Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins.
Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.
Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a choline moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and choline and 2 moles of fatty acids.
Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to an ethanolamine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and ethanolamine and 2 moles of fatty acids.
Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.
Relating to the size of solids.
Positively charged atoms, radicals or groups of atoms which travel to the cathode or negative pole during electrolysis.
Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a serine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and serine and 2 moles of fatty acids.
A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.
A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.
Layers of lipid molecules which are two molecules thick. Bilayer systems are frequently studied as models of biological membranes.
Synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of PULMONARY SURFACTANTS.
Single membrane vesicles, generally made of PHOSPHOLIPIDS.
The chemical and physical integrity of a pharmaceutical product.
Protein-lipid combinations abundant in brain tissue, but also present in a wide variety of animal and plant tissues. In contrast to lipoproteins, they are insoluble in water, but soluble in a chloroform-methanol mixture. The protein moiety has a high content of hydrophobic amino acids. The associated lipids consist of a mixture of GLYCEROPHOSPHATES; CEREBROSIDES; and SULFOGLYCOSPHINGOLIPIDS; while lipoproteins contain PHOSPHOLIPIDS; CHOLESTEROL; and TRIGLYCERIDES.
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
Lipids, predominantly phospholipids, cholesterol and small amounts of glycolipids found in membranes including cellular and intracellular membranes. These lipids may be arranged in bilayers in the membranes with integral proteins between the layers and peripheral proteins attached to the outside. Membrane lipids are required for active transport, several enzymatic activities and membrane formation.
The preparation, mixing, and assembling of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814)
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
The adherence and merging of cell membranes, intracellular membranes, or artificial membranes to each other or to viruses, parasites, or interstitial particles through a variety of chemical and physical processes.
Derivatives of ammonium compounds, NH4+ Y-, in which all four of the hydrogens bonded to nitrogen have been replaced with hydrocarbyl groups. These are distinguished from IMINES which are RN=CR2.
A nitrogen-free class of lipids present in animal and particularly plant tissues and composed of one mole of glycerol and 1 or 2 moles of phosphatidic acid. Members of this group differ from one another in the nature of the fatty acids released on hydrolysis.
Property of membranes and other structures to permit passage of light, heat, gases, liquids, metabolites, and mineral ions.
The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH = log 1/2[1/(H+)], where (H+) is the hydrogen ion concentration in gram equivalents per liter of solution. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)
Differential thermal analysis in which the sample compartment of the apparatus is a differential calorimeter, allowing an exact measure of the heat of transition independent of the specific heat, thermal conductivity, and other variables of the sample.
A synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes.
Acidic phospholipids composed of two molecules of phosphatidic acid covalently linked to a molecule of glycerol. They occur primarily in mitochondrial inner membranes and in bacterial plasma membranes. They are the main antigenic components of the Wassermann-type antigen that is used in nontreponemal SYPHILIS SERODIAGNOSIS.
A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed)
The rate dynamics in chemical or physical systems.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Agents that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags.
Method of tissue preparation in which the tissue specimen is frozen and then dehydrated at low temperature in a high vacuum. This method is also used for dehydrating pharmaceutical and food products.
Preparation for electron microscopy of minute replicas of exposed surfaces of the cell which have been ruptured in the frozen state. The specimen is frozen, then cleaved under high vacuum at the same temperature. The exposed surface is shadowed with carbon and platinum and coated with carbon to obtain a carbon replica.
The motion of phospholipid molecules within the lipid bilayer, dependent on the classes of phospholipids present, their fatty acid composition and degree of unsaturation of the acyl chains, the cholesterol concentration, and temperature.
Nanometer-sized, hollow, spherically-shaped objects that can be utilized to encapsulate small amounts of pharmaceuticals, enzymes, or other catalysts (Glossary of Biotechnology and Nanobiotechnology, 4th ed).
The property of objects that determines the direction of heat flow when they are placed in direct thermal contact. The temperature is the energy of microscopic motions (vibrational and translational) of the particles of atoms.
Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.
The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.
Artificially produced membranes, such as semipermeable membranes used in artificial kidney dialysis (RENAL DIALYSIS), monomolecular and bimolecular membranes used as models to simulate biological CELL MEMBRANES. These membranes are also used in the process of GUIDED TISSUE REGENERATION.
Particles consisting of aggregates of molecules held loosely together by secondary bonds. The surface of micelles are usually comprised of amphiphatic compounds that are oriented in a way that minimizes the energy of interaction between the micelle and its environment. Liquids that contain large numbers of suspended micelles are referred to as EMULSIONS.
N(2)-((1-(N(2)-L-Threonyl)-L-lysyl)-L-prolyl)-L-arginine. A tetrapeptide produced in the spleen by enzymatic cleavage of a leukophilic gamma-globulin. It stimulates the phagocytic activity of blood polymorphonuclear leukocytes and neutrophils in particular. The peptide is located in the Fd fragment of the gamma-globulin molecule.
Measurement of the intensity and quality of fluorescence.
The branch of medicine concerned with the application of NANOTECHNOLOGY to the prevention and treatment of disease. It involves the monitoring, repair, construction, and control of human biological systems at the molecular level, using engineered nanodevices and NANOSTRUCTURES. (From Freitas Jr., Nanomedicine, vol 1, 1999).
A carrier or inert medium used as a solvent (or diluent) in which the medicinally active agent is formulated and or administered. (Dictionary of Pharmacy, 1986)
Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen.
Characteristics or attributes of the outer boundaries of objects, including molecules.
Fatty acids which are unsaturated in only one position.
A complex mixture of PHOSPHOLIPIDS; GLYCOLIPIDS; and TRIGLYCERIDES; with substantial amounts of PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; and PHOSPHATIDYLINOSITOLS, which are sometimes loosely termed as 1,2-diacyl-3-phosphocholines. Lecithin is a component of the CELL MEMBRANE and commercially extracted from SOYBEANS and EGG YOLK. The emulsifying and surfactant properties are useful in FOOD ADDITIVES and for forming organogels (GELS).
Nanometer-sized particles that are nanoscale in three dimensions. They include nanocrystaline materials; NANOCAPSULES; METAL NANOPARTICLES; DENDRIMERS, and QUANTUM DOTS. The uses of nanoparticles include DRUG DELIVERY SYSTEMS and cancer targeting and imaging.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Any compound containing one or more monosaccharide residues bound by a glycosidic linkage to a hydrophobic moiety such as an acylglycerol (see GLYCERIDES), a sphingoid, a ceramide (CERAMIDES) (N-acylsphingoid) or a prenyl phosphate. (From IUPAC's webpage)
Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics.

Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. (1/9099)

Increased breast cancer growth has been associated with increased expression of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases (RTKs). Upon activation, RTKs may transmit their oncogenic signals by binding to the growth factor receptor bound protein-2 (Grb2), which in turn binds to SOS and activates the Ras/Raf/MEK/mitogen-activated protein (MAP) kinase pathway. Grb2 is important for the transformation of fibroblasts by EGFR and ErbB2; however, whether Grb2 is also important for the proliferation of breast cancer cells expressing these RTKs is unclear. We have used liposomes to deliver nuclease-resistant antisense oligodeoxynucleotides (oligos) specific for the GRB2 mRNA to breast cancer cells. Grb2 protein downregulation could inhibit breast cancer cell growth; the degree of growth inhibition was dependent upon the activation and/or endogenous levels of the RTKs. Grb2 inhibition led to MAP kinase inactivation in EGFR, but not in ErbB2, breast cancer cells, suggesting that different pathways might be used by EGFR and ErbB2 to regulate breast cancer growth.  (+info)

Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism. (2/9099)

Parkinson's disease is a neurodegenerative disorder characterized by the depletion of dopamine in the caudate putamen. Dopamine replacement with levodopa, a precursor of the neurotransmitter, is presently the most common treatment for this disease. However, in an effort to obtain better therapeutic results, tissue or cells that synthesize catecholamines have been grafted into experimental animals and human patients. In this paper, we present a novel technique to express tyrosine hydroxylase (TH) in the host's own astrocytes. This procedure uses a transgene in which the expression of a TH cDNA is under the control of a glial fibrillary acidic protein (GFAP) promoter, which confers astrocyte-specific expression and also increases its activity in response to brain injury. The method was tested in a rat model of Parkinson's disease produced by lesioning the striatum with 6-hydroxydopamine. Following microinjection of the transgene into the denervated striatum as a DNA-liposome complex, expression of the transgene was detected by RT-PCR and TH protein was observed specifically in astrocytes by using double-labeling immunofluorescence for GFAP and TH coupled with laser confocal microscopy. Efficacy was demonstrated by significant behavioral recovery, as assessed by a decrease in the pharmacologically induced turning behavior generated by the unilateral denervation of the rat striatum. These results suggest this is a valuable technique to express molecules of therapeutic interest in the brain.  (+info)

Gating connexin 43 channels reconstituted in lipid vesicles by mitogen-activated protein kinase phosphorylation. (3/9099)

The regulation of gap junctional permeability by phosphorylation was examined in a model system in which connexin 43 (Cx43) gap junction hemichannels were reconstituted in lipid vesicles. Cx43 was immunoaffinity-purified from rat brain, and Cx43 channels were reconstituted into unilamellar phospholipid liposomes. The activities of the reconstituted channels were measured by monitoring liposome permeability. Liposomes containing the Cx43 protein were fractionated on the basis of permeability to sucrose using sedimentation in an iso-osmolar density gradient. The gradient allowed separation of the sucrose-permeable and -impermeable liposomes. Liposomes that were permeable to sucrose were also permeable to the communicating dye molecule lucifer yellow. Permeability, and therefore activity of the reconstituted Cx43 channels, were directly dependent on the state of Cx43 phosphorylation. The permeability of liposomes containing Cx43 channels was increased by treatment of liposomes with calf intestinal phosphatase. Moreover, liposomes formed with Cx43 that had been dephosphorylated by calf intestinal phosphatase treatment showed increased permeability to sucrose. The role of phosphorylation in the gating mechanism of Cx43 channels was supported further by the observation that phosphorylation of Cx43 by mitogen-activated protein kinase reversibly reduced the permeability of liposomes containing dephosphorylated Cx43. Our results show a direct correlation between gap junctional permeability and the phosphorylation state of Cx43.  (+info)

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. (4/9099)

In August 1997, AmBisome (liposomal amphotericin B, Nexstar, San Dimas, CA) was the first drug approved for the treatment of visceral leishmaniasis by the U.S. Food and Drug Administration. The growing recognition of emerging and reemerging infections warrants that safe and effective agents to treat such infections be readily available in the United States. The following discussion of the data submitted in support of the New Drug Application for AmBisome for the treatment of visceral leishmaniasis shows the breadth of data from clinical trials that can be appropriate to support approval for drugs to treat tropical diseases.  (+info)

Systemic candidiasis with candida vasculitis due to Candida kruzei in a patient with acute myeloid leukaemia. (5/9099)

Candida kruzei-related systemic infections are increasing in frequency, particularly in patients receiving prophylaxis with antifungal triazoles. A Caucasian male with newly diagnosed acute myeloid leukaemia (AML M1) developed severe and persistent fever associated with a micropustular eruption scattered over the trunk and limbs during induction chemotherapy. Blood cultures grew Candida kruzei, and biopsies of the skin lesions revealed a candida vasculitis. He responded to high doses of liposomal amphotericin B and was discharged well from hospital.  (+info)

Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey. (6/9099)

Liposomal aminoglycosides have been shown to have activity against intracellular infections, such as those caused by Mycobacterium avium. Amikacin in small, low-clearance liposomes (MiKasome) also has curative and prophylactic efficacies against Pseudomonas aeruginosa and Klebsiella pneumoniae. To develop appropriate dosing regimens for low-clearance liposomal amikacin, we studied the pharmacokinetics of liposomal amikacin in plasma, the level of exposure of plasma to free amikacin, and urinary excretion of amikacin after the administration of single-dose (20 mg/kg of body weight) and repeated-dose (20 mg/kg eight times at 48-h intervals) regimens in rhesus monkeys. The clearance of liposomal amikacin (single-dose regimen, 0.023 +/- 0.003 ml min-1 kg-1; repeated-dose regimen, 0.014 +/- 0.001 ml min-1 kg-1) was over 100-fold lower than the creatinine clearance (an estimate of conventional amikacin clearance). Half-lives in plasma were longer than those reported for other amikacin formulations and declined during the elimination phase following administration of the last dose (from 81.7 +/- 27 to 30.5 +/- 5 h). Peak and trough (48 h) levels after repeated dosing reached 728 +/- 72 and 418 +/- 60 micrograms/ml, respectively. The levels in plasma remained > 180 micrograms/ml for 6 days after the administration of the last dose. The free amikacin concentration in plasma never exceeded 17.4 +/- 1 micrograms/ml and fell rapidly (half-life, 1.47 to 1.85 h) after the administration of each dose of liposomal amikacin. This and the low volume of distribution (45 ml/kg) indicate that the amikacin in plasma largely remained sequestered in long-circulating liposomes. Less than half the amikacin was recovered in the urine, suggesting that the level of renal exposure to filtered free amikacin was reduced, possibly as a result of intracellular uptake or the metabolism of liposomal amikacin. Thus, low-clearance liposomal amikacin could be administered at prolonged (2- to 7-day) intervals to achieve high levels of exposure to liposomal amikacin with minimal exposure to free amikacin.  (+info)

Morphological behavior of acidic and neutral liposomes induced by basic amphiphilic alpha-helical peptides with systematically varied hydrophobic-hydrophilic balance. (7/9099)

Lipid-peptide interaction has been investigated using cationic amphiphilic alpha-helical peptides and systematically varying their hydrophobic-hydrophilic balance (HHB). The influence of the peptides on neutral and acidic liposomes was examined by 1) Trp fluorescence quenched by brominated phospholipid, 2) membrane-clearing ability, 3) size determination of liposomes by dynamic light scattering, 4) morphological observation by electron microscopy, and 5) ability to form planar lipid bilayers from channels. The peptides examined consist of hydrophobic Leu and hydrophilic Lys residues with ratios 13:5, 11:7, 9:9, 7:11, and 5:13 (abbreviated as Hels 13-5, 11-7, 9-9, 7-11, and 5-13, respectively; Kiyota, T., S. Lee, and G. Sugihara. 1996. Biochemistry. 35:13196-13204). The most hydrophobic peptide (Hel 13-5) induced a twisted ribbon-like fibril structure for egg PC liposomes. In a 3/1 (egg PC/egg PG) lipid mixture, Hel 13-5 addition caused fusion of the liposomes. Hel 13-5 formed ion channels in neutral lipid bilayer (egg PE/egg PC = 7/3) at low peptide concentrations, but not in an acidic bilayer (egg PE/brain PS = 7/3). The peptides with hydrophobicity less than Hel 13-5 (Hels 11-7 and Hel 9-9) were able to partially immerse their hydrophobic part of the amphiphilic helix in lipid bilayers and fragment liposome to small bicelles or micelles, and then the bicelles aggregated to form a larger assembly. Peptides Hel 11-7 and Hel 9-9 each formed strong ion channels. Peptides (Hel 7-11 and Hel 5-13) with a more hydrophilic HHB interacted with an acidic lipid bilayer by charge interaction, in which the former immerses the hydrophobic part in lipid bilayer, and the latter did not immerse, and formed large assemblies by aggregation of original liposomes. The present study clearly showed that hydrophobic-hydrophilic balance of a peptide is a crucial factor in understanding lipid-peptide interactions.  (+info)

Identification of mechanosensitive ion channels in the cytoplasmic membrane of Corynebacterium glutamicum. (8/9099)

Patch-clamp experiments performed on membrane fragments of Corynebacterium glutamicum fused into giant liposomes revealed the presence of two different stretch-activated conductances, 600 to 700 pS and 1,200 to 1,400 pS in 0.1 M KCl, that exhibited the same characteristics in terms of kinetics, ion selectivity, and voltage dependence.  (+info)

Progressive aggregation of protein Tau into oligomers and fibrils correlates with cognitive decline and synaptic dysfunction, leading to neurodegeneration in vulnerable brain regions in Alzheimers disease. The unmet need of effective therapy for Alzheimers disease, combined with problematic pharmacological approaches, led the field to explore immunotherapy, first against amyloid peptides and recently against protein Tau. Here we adapted the liposome-based amyloid vaccine that proved safe and efficacious, and incorporated a synthetic phosphorylated peptide to mimic the important phospho-epitope of protein Tau at residues pS396/pS404. We demonstrate that the liposome-based vaccine elicited, rapidly and robustly, specific antisera in wild-type mice and in Tau.P301L mice. Long-term vaccination proved to be safe, because it improved the clinical condition and reduced indices of tauopathy in the brain of the Tau.P301L mice, while no signs of neuro-inflammation or other adverse neurological effects were
Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components
The incorporation of poly(ethylene glycol) (PEG)-conjugated lipids in lipid-based carriers substantially prolongs the circulation lifetime of liposomes. However, the mechanism(s) by which PEG-lipids achieve this have not been fully elucidated. It is believed that PEG-lipids mediate steric stabilization, ultimately reducing surface-surface interactions including the aggregation of liposomes and/or adsorption of plasma proteins. The purpose of the studies described here was to compare the effects of PEG-lipid incorporation in liposomes on protein binding, liposome-liposome aggregation and pharmacokinetics in mice. Cholesterol-free liposomes were chosen because of their increasing importance as liposomal delivery systems and their marked sensitivity to protein binding and aggregation. Specifically, liposomes containing various molecular weight PEG-lipids at a variety of molar proportions were analyzed for in vivo clearance, aggregation state (size exclusion chromatography, quasi-elastic light ...
Comparison of liposome-based transfection reagents hr...Transfection of mammalian cell lines is enhanced by the use oflipos...Our lab has recently been interested in the transient transfection of ...The cell line used for many of our experiments is the human adrenalcar...,Transfection,of,Green,Fluorescent,Protein,into,Human,Adrenalcarcinoma,Cells,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
Quantum dots (QDs) and silica nanoparticles (SNs) are new classes of fluorescent probes that overcome the limitations encountered by organic fluorophores in bioassay and biological imaging applications. We encapsulated QDs and SNs into liposomes by the reverse-phase evaporation method. Nanoparticle-loaded liposomes were separated from unencapsulated nanoparticles by size exclusion chromatography and their characteristics were investigated. Dual-color, two-photon fluorescence correlation spectroscopy was used to measure the number of nanoparticles inside each liposome. Results indicated that nanoparticle-loaded liposomes were formed and separated from unencapsulated nanoparticles by using Sepharose gel. As expected, fluorescence self-quenching of nanoparticles inside liposomes was not observed. When a 0.8 mM solution of 50 nm QDs was used for liposome preparation, each liposome encapsulated an average of three QDs. However, we could not measure the number of SNs inside each liposome due to the spectral
In this thesis, the method development and investigation of different liposomal formulations to incorporate and retain Camptothecin (CPT) is described. CPT is a potent anticancer drug that has shown to be active against a broad spectrum of cancers. However, due to its challenging physicochemical properties, like poor water solubility, severe toxic effects to normal tissues and instability, its clinical development has been limited for nearly 40 years. A strategy to overcome CPTs challenging properties is to use liposome-based carrier system. By taking advantage of this carrier system, we may solubilise CPT in the phospholipid bilayer of liposomes, protect it from blood proteins and achieve a selective drug accumulation in tumor tissues or tumor-associated cells by enhanced permeability and retention effect (EPR). A good liposome formulation of clinical utility must fulfil two important criteria. The liposomal drug carrier must incorporate CPT in the liposomal bilayer in a relevant therapeutic ...
A promising strategy to improve the immunogenic potential of DNA vaccines is the formulation of plasmid DNA (pDNA) with cationic liposomes. In this respect, particle size may be of crucial importance. This study aimed at the evaluation of high-pressure extrusion as a method for sizing cationic liposomes after entrapment of pDNA. This is a well-known sizing method for liposomes, but so far, it has not been applied for liposomes that are already loaded with pDNA. Liposomes composed of egg PC, DOTAP, and DOPE with entrapped pDNA were prepared by the dehydration-rehydration method and subjected to various extrusion cycles, comparing different membrane pore sizes and extrusion frequencies. At optimized extrusion conditions, liposome diameter (Zave) and polydispersity index (PDI) were reduced from 560 nm and 0.56 to 150 nm and 0.14 respectively, and 35% of the pDNA was retained. Importantly, gel electrophoresis and transfection experiments with pDNA extracted from these extruded liposomes demonstrated ...
TY - JOUR. T1 - Liposomal drug delivery system. AU - Maruyama, Kazuo. AU - Kennel, Stephen. AU - Huang, Leaf. PY - 1990/8/1. Y1 - 1990/8/1. N2 - We have recently described an immunoliposome targeting system which involves the use of monoclonal antibodies specific for the pulmonary endothelial cells. We have employed the antibodies, 34A and 201B, which bind to a surface glycoprotein, gp112, which is specifically expressed in high concentrations in the capillary endothelial cells of the mouse lung. Intravenously injected immunoliposomes (34A- or 201B-liposomes) to the mice gain direct access and bind efficiently to the lung. Approximately 50% of the injected dose was accumulated in the lung for 34A-liposomes which contained an average of 935 antibody molecules per liposome. Lung accumulation of 34A-liposomes is completely blocked by a preinjection of free antibody 34A, indicating that the immunoliposome accumulation at the target site is immunospecific. The level of lung accumulation increases ...
Another new technology to increase the accumulation of liposomes at the target site is immunoliposomes. Immunoglobulins, especially those of the IgG class, are attached to the surface of the liposomes. They act as ligands-molecules that connect to a site on a receptor protein-capable of recognizing and binding to tissue at sites of interest. However, most immunoliposomes are still eliminated by the liver before they can deliver significant results. One way to meet this challenge is to use stealth liposome technology: Coat the immunoliposomes with PEG to create long-circulating liposomes. Currently, one immunoliposome formulation is in clinical trials, a PEGylated DXR formulated to recognize gastric, colon, and breast cancer cells ...
The invention discloses a formula of a liposome preparation containing compound amino acids and a preparation method thereof; a raw material mass ratio of the liposome preparation is determined; the preparation method comprises the following steps: (1) weighing soybean phosphatide and cholesterol, adding water, heating and stirring to prepare an oil phase; (2) weighing cysteine hydrochloride and tryptophan, adding process water for dissolution, orderly adding some or all of valine, isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, arginine, glycine, and praline; then orderly adding one or more than one of auxiliary materials of vitamin A, vitamin C, vitamin E, and vitamin K, and a film forming material, finally adding potassium sorbate or ethylparaben, stirring toprepare a water phase; (3) mixing the oil phase and the water phase, shearing by a high-speed shearing machine to obtain the liposome preparation. The invention initiates the technology for preparingliposome ...
Liposomal glutathione is a certain type of supplement. Liposomal supplements offer a delivery system that ensures effective delivery into the cells and rapid uptake.. Liposomes are especially good as an antioxidant delivery system because theyre prepared from natural phospholipids, are biocompatible and are nontoxic.. What all this means in simpler terms is that liposomal delivery systems are a good way to take supplements like glutathione because they protect the therapeutic molecules from breaking down in your digestive system.. Typically when you take a supplement, and especially one thats not normally that bioavailable like glutathione, much of the value is lost by the time it reaches your cells because it breaks down in your digestive system.. The goal is to get as much of the value of the glutathione to your cells as possible, which can be achieved through liposomal delivery.. Research found that liposomes can increase cellular delivery 100 times over non-liposomal ...
BISAC: SCI017000. Chapter One is addressed to a comprehensive revision of the bibliography regarding the emergence of liposomes and the first steps in their design, the type of systems (components and structures), their classification and properties. Chapter Two discusses the possibility of creating living synthetic cells. Chapter Three provides an overview of the development and application of liposomes in biomedical sciences, with special emphasis on recent advances in the investigation of multifunctional liposomes that target cells and cellular organelles with a single delivery system. In Chapter Four, the authors review the mechanisms of drug transport through the BBB using liposomes, and the design strategies for optimum liposomal properties. In Chapter Five, the development rationales and structural types of pH-sensitive liposomes is discussed Chapter Six presents the characteristic, classification and preparation methods of liposomes. To develop liposomal drug delivery system, ...
Liposomes which substantially avoid uptake into the mononuclear phagocyte system (MPS), termed Stealth liposomes, have recently been formulated (Allen, T.M. and Chonn, A., (1987) FEBS Lett. 223, 42-46). The pharmacokinetics of stealth liposomes as a function of liposome dose and a comparison to conv …
Soft nanogels are submicron-sized hydrophilic structures engineered from biocompatible polymers possessing the characteristics of nanoparticles as well as hydrogels, with a wide array of potential applications in biotechnology and biomedicine, namely, drug and protein delivery. In this work, nanogels were obtained using the physical self-assembly technique or layer-by-layer which is based on electrostatic interactions. Liposomal vesicles were coated with alternating layers of hyaluronic acid and chitosan yielding a more viscous hydrogel formulation that previously reported core-shell nanoparticulate suspension, via simply modifying the physico-chemical characteristics of the system. Structural features, size, surface charge, stability and swelling characteristics of the nanogel were studied using scanning electron microscopy and dynamic light scattering. With a specific cranio-maxillofacial application in mind, the hydrogel was loaded with recombinant human (rh) bone morphogenetic protein-7, also
LIPOSOMES can encapsulate and transport water-soluble ingredients in their polar cavity and oil-soluble ingredients in their hydrophobic cavity. ​. el-e-ments uses liposome encapsulations as a delivery system for important actives as well as Vitamins A, B3, B5, C and E for enhanced protection and skin nutrition. The liposome encapsulation ensures delivery into the tissues where the actives can work to improve moisturization, reduce inflammation, the appearance of spots, uneven skin tone and loss of elasticity all of the support that your skin health ingredient actives need to truly perform with optimal entourage and bio-availability. Liposomes deliver the power of the vital nutrients deep into the tissues, making them 10x more effective than the vitamins alone. ...
Doxorubicin Hydrochloride Liposome Injection by UNITED BIOTECH (P) LTD, Manufacturer, Supplier, Exporter of Doxorubicin HCl Liposome Injection. Call Now.
Computer-assisted motion analyses (CASA) and flow cytometry were used to evaluate stallion spermatozoa prior to and after cryopreservation. Spermatozoa were pretreated with: (1) Hepes-buffered medium (SHB); (2) phosphatidylserine (PS) liposomes; or (3) liposomes composed of both PS and cholesterol (PSCH) prior to dilution in either SHB or skim milk-egg yolk extender (SMEY). After cooling to 5 degrees C in SHB, PS and PSCH pretreatment (23%). Spermatozoal motion parameters were higher for spermatozoa diluted in SMEY than dilution in SHB. In Experiment 2, motion parameters were compared for spermatozoa pretreated with PSCH liposomes and cryopreserved in either SMEY or a high salt-skim milk-egg yolk extender (CO). Spermatozoal motion characteristics were similar for all spermatozoal treatments after cooling at 5 degrees C. After cryopreservation, PSCH liposome-treated samples had higher percentages of motile spermatozoa than untreated samples regardless of freezing extender. Samples frozen in CO medium had
The study of different strategies to improve the stability and bioavailability of bioactive components has increased in the last decades. One of the mechanisms that has acquired great relevance is to formulate using liposomal vesicles. Liposomes are structures that enhance the absorption, stability and transport of active compounds, which is reflected by an increase in the bioactivity of the encapsulated molecules. The guarana extract has proven to be rich in methylxanthines and phenolic compounds. These metabolites are associatedto a wide variety of pharmacological properties, and exert a stimulating effect. For this reason, it has become popular in nutritional products. In this workit was characterized physicochemically a nutritional product based on guarana, vitamins and folic acid. In this product the active components were encapsulated in liposomal vesicles, which were analyzed to know their structure, size (diameter) and membrane thickness. Results and analysis indicate that liposomes are ...
Title:Comparison of Physicochemical Properties of Generic Doxorubicin HCl Liposome Injection with the Reference Listed Drug. VOLUME: 18 ISSUE: 4. Author(s):Kuntal Maiti *, Subhas Bhowmick, Pankaj Jain, Murlidhar Zope, Keyur Doshi and Thennati Rajamannar. Affiliation:Sun Pharma Advanced Research Company Ltd., Mumbai, Sun Pharmaceutical Industries Ltd. Mumbai, Sun Pharma Advanced Research Company Ltd., Mumbai, Sun Pharma Advanced Research Company Ltd., Mumbai, Sun Pharma Advanced Research Company Ltd., Mumbai, Sun Pharmaceutical Industries Ltd. Mumbai. Keywords:Doxorubicin hydrochloride, liposome, sterically stable, generic, physicochemical equivalence, cancer.. Abstract:Background: Liposomal doxorubicin is widely used for treating ovarian cancer and Kaposis sarcoma. Encapsulation of doxorubicin in highly complex polyethylene glycol-coated (stealth) liposomes prolongs residence time and avoids the systemic toxicity associated with administration of the free drug. Small variations in ...
In addition, we find binding of charged nanoparticles to the outer surface of phospholipid liposomes produces particle-stabilized liposomes that repel one another and do not fuse. Subsequently, the volume fraction can be raised as high as ∼50%, reversibly, still without fusion. In studies of liposome longevity, we verify the stability of particle-stabilized liposome suspensions with volume fraction up to 16% for up to 50 days, the longest period investigated. In contrast to the stabilized liposomes, the volume fraction of the same liposomes without nanoparticles is typically less than ∼2% with a longevity of 4∼5 days. Fluorescent dyes are encapsulated within the particle-stabilized liposomes, without leakage. Although these particle-stabilized liposomes are stable against fusion, ∼75% of the outer liposome surface remains unoccupied, which is still biofunctionalizable tested with ligand-receptor binding. This work not only provides a robust nanoparticle-liposome complex system which ...
Coating of liposomes with polyethylene glycol (PEG) has proven to prolong the circulation time of liposomes in the blood stream. PEG prevents the binding of opsonins and subsequent uptake of the liposomes by mononuclear phagocytic system (MPS). The reduction in clearance of PEGylated liposomes from the circulation improve the bioavailability of the liposomes in the blood and increase the chance of liposomes being accumulated in tumor tissue by the enhanced permeability and retention effect (EPR). The aim of this study was therefore to investigate the incorporation and retention ability of PEGylated liposome formulations of the anticancer agent Camptothecin (CPT), and further try to develop an immunoliposomal formulation of CPT targeting the EGFR receptors on the surface of colorectal cancer cells. The results from the incorporation and retention studies showed that the formulation consisting of 79 % egg phosphatidylcholine (EPC), 20 % 1,2-di-oleyl-3- trimethylammonium-propane (DOTAP) and 1 % PEG ...
There is a great need of improved anticancer drugs and corresponding drug carriers. In particular, liposomal drug carriers with heat-activated release and targeting functions are being developed for combined hyperthermia and chemotherapy treatments of tumors. The aim of this study is to demonstrate the heat-activation of liposome targeting to biotinylated surfaces, in model experiments where streptavidin is used as a pretargeting protein. The design of the heat-activated liposomes is based on liposomes assembled in an asymmetric structure and with a defined phase transition temperature. Asymmetry between the inside and the outside of the liposome membrane was generated through the enzymatic action of phospholipase D, where lipid head groups in the outer membrane leaflet, i.e. exposed to the enzyme, were hydrolyzed. The enzymatically treated and purified liposomes did not bind to streptavidin-modified surfaces. When activation heat was applied, starting from 22 degrees C, binding of the liposomes
This report aims to target already-existing systems that could enable the use of cloaking concepts in order to achieve control of three-dimensional processes, using coated spheres consisting of concentric layers of homogeneous isotropic diffusivity. Various applications already implicate the use of concentric bilayered vesicles, one example being liposomes used for drug delivery [1]. Liposomes are concentric bilayered vesicles in which an aqueous volume containing a water-soluble drug is enclosed by a membranous lipid bilayer composed of natural or synthetic phospholipids. One popular type of liposomes, known as the stealth liposomes [2], are highly stable, long-circulating liposomes whereby polyethylene glycol has been used as the polymeric steric stabilizer [3]. Stealth and other liposomes use the concept of invisibility in order to hide and evade the immunosystem by coupling water-soluble polymers to the lipid heads. Therefore, the polymer part of the molecule is dissolved in the aqueous ...
Specific targeting of liposome-formulated cytotoxic drugs or antigens to receptors expressed selectively on target cells represents an effective strategy for increasing the pharmacological efficacy of the delivered molecules. We have developed a feasible technique to selectively attach antibodies and fragments thereof, but also small-mol-wt ligands such as peptides, carbohydrates, or any molecules that recognize and bind target antigens or receptors to the surface of small unilamellar liposomes. Our concept is based on the site-specific functionalization of the ligands to be attached to the liposomes by thiol groups. These thiol groups can easily be introduced to antibodies or peptides by addition of cysteines, preferably at sites that do not interfere with the receptor binding domains. Optimally, the site-specific modification is introduced at the C-terminal end of the ligand, separated by an inert spacer sequence located between the thiols and the specific part of the ligand. The ...
Detection of biomolecules and biological nanoparticles by means of induced aggregation of larger nanoparticles using light scattering as readout was first accomplished in the middle of the last century. Since then, technical advances together with novel nanomaterials have enabled more sophisticated readout schemes, paving the way for methods exploiting dual-probe hybridization for biomolecular or nonoparticle recognition that today can compete with established bioanalytical methods. Herein, we present a quantitative assay, with single-nanoparticle readout, utilizing receptor-containing cell-membrane mimics in the shape of approximately 100-nm lipid liposomes rather than conventional antibody-modified nanoparticles to enable detection of virus particles in solution. Specifically, the method is based on virus-mediated aggregation of differently fluorescent-labeled liposomes that contain the ganglioside GM1 receptor for the Simian Virus 40 (SV40). The aggregation kinetics of the differently colored
DescriptionMethicillin Resistant Staphylococcus aureus (MRSA) causes a myriad of infections ranging from mild skin-infection to more serious infections affecting internal organs. A glycopeptide, Vancomycin, remains the last line of defense against MRSA. The aim of this study is to investigate whether liposomal encapsulated Vancomycin had a better antimicrobial action than free Vancomycin in terms of infection-specific targeting and circulation time. For the same, encapsulation efficiency and release kinetics of the liposomes was evaluated along with Minimum Inhibitory Concentrations (MIC) of the liposomal preparations. The liposomes showcased a 12-15% encapsulation efficiency. Sustained release at pH 6.0 as compared to little to no release at pH 7.4 was demonstrated by the pH sensitive liposomes. Also, in acidic pH, an increase in efficacy was observed with a greater decrease in the MIC of the pH responsive liposomes as compared to the lower decrease in MIC of the non pH-responsive liposomes and ...
The liposome, a closed phospholipid bilayered vesicular system, has received considerable attention as a pharmaceutical carrier of great potential over the past 30 years. The ability of liposomes to encapsulate both hydrophilic and hydrophobic drugs, coupled with their biocompatibility and biodegradability, make liposomes attractive vehicles in the field of drug delivery. In addition, great technical advances such as remote drug loading, triggered release liposomes, ligand-targeted liposomes, liposomes containing combinations of drugs, and so on, have led to the widespread use of liposomes in diverse areas as delivery vehicles for anti-cancer, bio-active molecules, diagnostics, and therapeutic agents ...
In the tumor microenvironment, cytokines, growth factors, and oncogenes mediate constitutive activation from the signal transducer and activator of transcription 3 (STAT3) signaling pathway in both cancer cells and infiltrating immune cells. been shown to eliminate tumors through immune modulation. treatment of NSCLC with phenethyl isothiocyanate. For each of the studies reviewed, the formulation of phospholipids, the cholesterol content and the percentage of polyethylene glycol conjugated lipids differed. These differences can significantly impact treatment efficacy by affecting pharmacokinetics of ETP-46321 drug release and uptake profiles into phagocytic cells [22]. However, given the limited number of studies on liposomal delivery for each natural STAT3 inhibitor and the various cancer models that rarely match between studies, it was not possible to evaluate the effect of liposome compositions on drug efficacy. As more studies emerge on liposomal delivery of STAT3 inhibitors, hopefully the ...
In one method, DNA fragments, of approximately 2-200 bases in length, or deoxynucleotides (single bases), are administered topically to the epidermis, either in a liposome preparation or in another appropriate vehicle, such as propylene glycol, in a quantity sufficient to enhance melanin production. As used herein, DNA fragments refers to single-stranded DNA fragments, double-stranded DNA fragments, a mixture of both single-and double-stranded DNA fragments, or deoxynucleotides. Deoxynucleotides refers to either a single type of deoxynucleotide or a mixture of different deoxynucleotides. The DNA fragments or deoxynucleotides can come from any appropriate source. For example, salmon sperm DNA can be dissolved in water, and then the mixture can be autoclaved to fragment the DNA. The fragments can additionally be UV-irradiated. The liposome preparation can be comprised of any liposomes which penetrate the stratum corneum and fuse with the cell membrane, resulting in delivery of the contents of ...
There are about 20 publications about liposomal formulations of Cyclosporin A (CyA) in the pharmaceutical and preclinical literature. Liposomal formulations were developed in order to reduce the nephrotoxicity of CyA and to increase pharmacological effects. However, conflicting results have been published as to the therapeutic properties of these formulations. This is also true for the change in pharmacokinetics and organ distribution of the liposomally encapsulated CyA as compared to conventionally formulated CyA. Using biophysical methods, it could be shown that CyA is not tightly entrapped in liposomal membranes, despite its high lipophilicity. CyA shows retardation only at high lipid concentrations in blood, following a massive injection of liposomes.This effect may diminish nephrotoxicity, as could be demonstrated by in vitro studies using a model tubule system. The results of these studies can be used to predict the formulation behavior in vivo and to optimize liposomal formulations. When ...
Elixinols new rapidly dissolving Hemp Oil Liposomes are the latest enhancements to cannabinoid delivery. Now you can receive cannabinoids into the body faster, deeper and easier than ever before. With 100% natural fruit and herb extracts, this is a delicious hemp oil supplement you will enjoy taking daily without any bitter taste.Product informationThis 3.5 oz (100 ml) spray pump dispenser bottle of Elixinol™ Liposome contains 1000 mg of cannabidiol extract (CBD hemp oil) with a citrus flavor.How our hemp oil liposomes are madeWe pre-dissolve our CBD hemp oil and embed it into microscopic liposomes. This safe technology allows you to absorb more cannabinoids with the aid of naturally occurring phospholipids. These support cellular health and delivery of cannabidiol and other cannabinoids directly into the cell.The reason that liposomes are so effective is that hemp oil, in its natural form, is a sticky dense oil. As you may know, getting any oil-based substance to pass through a cell wall is a
Read DNA-Induced Aggregation and Fusion of Phosphatidylcholine Liposomes in the Presence of Multivalent Cations Observed by the Cryo-TEM Technique, The Journal of Membrane Biology on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
Much of the work on liposomal drug delivery has focused on cancer treatment because conventionally delivered cancer chemotherapy has been far from satisfactory. Major problems with conventional chemotherapy are the inability of the drug to reach the tumor site at pharmacologically active concentrations, intrinsic as well as acquired cross-resistance to multiple chemotherapeutic agents, and toxicity that contributes to many of the treatment failures.. Doxorubicin encapsulated in long-circulating, PEGylated liposomes has proven to be more effective than the free drug in several tumor models, including murine tumors and human tumor xenografts, regardless of tumor type and site of implantation (27) . In all of the experiments conducted, the liposomal preparation clearly performed better than Free-Dox, and the peak tumor drug levels obtained by liposome delivery were at least 3-fold greater. Notable differences in toxicity between free drug and liposomal drug have also been observed, including ...
Kawakami, S.; Suzuki, S.; Yamashita, F.; Hashida, M., 2005: Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes
TY - JOUR. T1 - Direct Comparison of Standard Transmission Electron Microscopy and Cryogenic-TEM in Imaging Nanocrystals Inside Liposomes. AU - Li, Tang. AU - Nowell, Cameron J.. AU - Cipolla, David. AU - Rades, Thomas. AU - Boyd, Ben J.. PY - 2019/4/1. Y1 - 2019/4/1. N2 - The use of electron microscopy techniques in the understanding of shape and size of nanoparticles are commonly applied to drug nanotechnology, but the type of microscopy and suitability for the particles of interest can have a significant impact on the result. The size and shape of the nanoparticles are crucial in clinical applications; however, direct comparison of the results from standard transmission electron microscopy (TEM) and cryo-TEM have rarely been reported. As a useful case for comparison, liposomal drug nanocrystals are studied here. In this study, the effect of thawing temperature on the size and shape of the ciprofloxacin nanocrystals was determined. A quantitative standard TEM assay was developed to allow for ...
A new technique for the quantification of cellular receptor-mediated endocytosis has been developed based on the analysis by flow cytometry of ligand-bearing liposomes containing the fluorochrome carboxyfluorescein. Carboxyfluorescein encapsulated at high concentrations in protein A-bearing liposomes is self-quenched. Binding and internalization of such liposomes by cells via antibodies directed towards membrane surface determinants results in the release of the liposome-encapsulated carboxyfluorescein into the cytoplasm causing an increase in cell-associated fluorescence. This increase can be quantified on a flow cytofluorometer. ...
Consumer information about the medication CYTARABINE LIPOSOME - INJECTION (Depocyt), includes side effects, drug interactions, recommended dosages, and storage information. Read more about the prescription drug CYTARABINE LIPOSOME - INJECTION.
The efficacy of a liposomal formulation for intracerebral delivery of borocaptate (BSH) to brain tumor cells has been investigated using cell culture to study BSH uptake and persistence and using tumor-bearing rats to determine BSH distribution in the brain. During a 16-hr incubation, cellular uptake of BSH solution or BSH liposomal formulation was similar. However, the cellular persistence of BSH greatly increased when BSH was present in liposome. The differences in cellular persistence for BSH solution and BSH-loaded liposomes were significant both in 12-hr and 24-hr incubation experiments (p | 0.05 and p | 0.01, respectively). For the studies involving tumor-bearing rats, BSH level in tumor tissue was significantly higher than that in normal brain tissue at 2 hr and 6 hr after intracerebral injection of BSH-loaded liposomes (p | 0.01). Our study indicated that the liposomal formulation enhanced cellular persistence of BSH in tumor cells and therefore favored the boron accumulation in the cells. With
1. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387-92 2. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189-207 3. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Controlled Release. 2012;164:138-44 4. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG. et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 2001;7:243-54 5. Allen C. Why Im holding onto hope for nano in oncology. Mol Pharm. 2016;13:2603-4 6. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583-92 7. Tan Q, Saggar JK, Yu M, Wang M, Tannock IF. Mechanisms of drug resistance related ...
We present a novel thylakoid based bio-solar cell capable of generating a photoelectric current of 0.7 µA/cm2. We have introduced an electro conductive polymer, PEDOT-S, to the thylakoid membrane. PEDOT-S intervenes in the photosynthesis, captures electrons from the electron transport chain and transfers them directly across the thylakoid membrane, thus generating a current. The incorporation of the electro conductive polymer into the thylakoid membrane is therefore vital for the function of the bio-solar cell. A liposomal model system based on liposomes formed by oleic acid was used to develop and study the incorporation of PEDOT-S to fatty acid membranes. The liposomes allow for a more controllable and easily manipulated system compared to the thylakoid membrane. In the model system, PEDOT-S could successfully be incorporated to the membrane, and the developed methods were applied to the real system of thylakoid membranes. We found that a bio-compatible electrolyte and redox couple was ...
Colloidal and interfacial phenomena lie at the core of drug formulation, drug delivery, as well as drug binding and action at diseased sites, e.g., in cancer therapy. We review a class of liposome-based drug-delivery systems whose design and functional properties are intimately controlled by the stability of sub-micron structures, lipid-bilayer interfaces, and interfacially activated enzymes that can be exploited to target and deliver drugs. Moreover these drugs can themselves be special lipid molecules in the form of lipid prodrugs that both form the liposomal carrier as well as the substrate for endogenously upregulated lipases that turn the prodrugs into potent drugs precisely at the diseased site. ...
Proteins and polysaccharide components were colocalized through a liposomal delivery system. LEPS liposomal carriers were composed of DOPC/DOPG/DOGS-NTA-Ni/cholesterol/DSPE-PEG2000 at a molar ratio of 3:3:1:4:0.1 to a total lipid mass of 500 μg. After dissolving lipids in chloroform, the solution was sonicated for 1 min using a Branson 450D Sonifier (at 20% amplitude using a tapered tip) and then evaporated using a rotary evaporator to form a film. Lipids were then rehydrated with phosphate-buffered saline (PBS) containing the polysaccharide antigens to form liposomes, which were then passed 10 to 12 times through a handheld extruder (Avanti Polar Lipids) with a pore size of 200 nm. On ice, the background liposome solution was passed twice through a filter with 50-nm pore size and replaced each time with PBS. Next, proteins were incubated with liposomes for 30 min at 4°C with surface attachment mediated via polyhistidine tag-Ni chelation. CRM197 was included in the LEPS formulations used for ...
The influence of vitamin D3 and its metabolites calcifediol (25(OH)D) and calcitriol on immune regulation and inflammation is well described, and raises the question of potential benefit against bacterial infections. In the current study, 25(OH)D was encapsulated in liposomes to enable aerosolisation, and tested for the ability to prevent pulmonary infection by Pseudomonas aeruginosa. Prepared 25(OH)D-loaded liposomes were nanosized and monodisperse, with a negative surface charge and a 25(OH)D entrapment efficiency of approximately 23%. Jet nebulisation of liposomes was seen to yield an aerosol suitable for tracheo-bronchial deposition. Interestingly, 25(OH)D in either liposomes or ethanolic solution had no effect on the release of the proinflammatory cytokine KC from Pseudomonas-infected murine epithelial cells (LA-4); treatment of infected, human bronchial 16-HBE cells with 25(OH)D liposomes however resulted in a significant reduction in bacterial survival. Together with the importance of ...
Giant Unilamellar Vesicles (GUVs) prepared from phospholipids are becoming popular membrane model systems for use in biophysical studies. The quality, size and yield of GUVs depend on the preparation method used to obtain them. In this study, hydrogels consisting of dextran polymers crosslinked by poly(ethyl
PEG altered the pharmacokinetic property of the DSPC/cholesterol liposomal doxorubicin by decreasing the Vss and clearance, and thereby increasing plasma AUC. These results are consistent with the notion that sterically stabilized liposome may reduce the RES uptake and enhance the longevity of liposomal doxorubicin in circulation, but above 3%, the gain in pharmacokinetic advantage was only slight. Compared with conventional liposomes, sterically stabilized liposomes have a 100-fold increase in AUC (3) . However, for the DSPC system used in this study, the AUC of liposomal doxorubicin with 6% PEG-modified lipid was only approximately twice that of liposomal doxorubicin without PEG, regardless of dosage or tumor-bearing status. Daunorubicin liposomes composed of DSPC/cholesterol without PEG also had a similar AUC (20) . The higher transition temperature and homogeneity in fatty acid of DSPC confers the higher stability to this DSPC/cholesterol liposomal system.. The movement of drugs from the ...
The use of liposomes has been crucial for investigations in biomimetic chemical biology as a membrane model and in medicinal chemistry for drug delivery. Liposomes are made of phospholipids whose biophysical characteristics strongly depend on the type of fatty acid moiety, where natural unsaturated lipids always have the double bond geometry in the cis configuration. The influence of lipid double bond configuration had not been considered so far with respect to the competence of liposomes in delivery. We were interested in evaluating possible changes in the molecular properties induced by the conversion of the double bond from cis to trans geometry. Here we report on the effects of the addition of trans-phospholipids supplied in different amounts to other liposome constituents (cholesterol, neutral phospholipids and cationic surfactants), on the size, ζ-potential and stability of liposomal formulations and on their ability to encapsulate two dyes such as rhodamine B and fluorescein. From a
Liposomes are proposed as drug delivery systems and can in principle be designed so as to cohere with specific tissue types or local environments. However, little detail is known about the exact mechanisms for drug delivery and the distributions of drug molecules inside the lipid carrier. In the current work, a coarse-grained (CG) liposome model is developed, consisting of over 2500 lipids, with varying degrees of drug loading. For the drug molecule, we chose hypericin, a natural compound proposed for use in photodynamic therapy, for which a CG model was derived and benchmarked against corresponding atomistic membrane bilayer model simulations. Liposomes with 21-84 hypericin molecules were generated and subjected to 10 microsecond simulations. Distribution of the hypericins, their orientations within the lipid bilayer, and the potential of mean force for transferring a hypericin molecule from the interior aqueous droplet through the liposome bilayer are reported herein.. ...
The well-known Toll like receptor 9 (TLR9) agonist CpG ODN has shown promising results as vaccine adjuvant in preclinical and clinical studies, however its in vivo stability and potential systemic toxicity remain a concern. In an effort to overcome these issues, different strategies have been explored including conjugation of CpG ODN with proteins or encapsulation/adsorption of CpG ODN into/onto liposomes. Although these methods have resulted in enhanced immunopotency compared to co-administration of free CpG ODN and antigen, we believe that this effect could be further improved. Here, we designed a novel delivery system of CpG ODN based on its conjugation to serve as anchor for liposomes. Thiol-maleimide chemistry was utilised to covalently ligate model protein with the CpG ODN TLR9 agonist. Due to its negative charge, the protein conjugate readily electrostatically bound cationic liposomes composed of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol and ...
TY - JOUR AU - Balanč, Bojana AU - Ota, Ajda AU - Đorđević, Verica AU - Sentjurc, Marjeta AU - Nedović, Viktor AU - Bugarski, Branko AU - Poklar-Ulrih, Nataša PY - 2015 UR - AB - The influence of resveratrol encapsulated into liposomes (prepared with a commercial lipid mixture of phospholipids, phospolipon 90NG, using the thin film and proliposome methods) on the structural properties of the liposome membrane was investigated by electron paramagnetic resonance (EPR) spectroscopy, fluorescence spectroscopy, and differential scanning calorimetry. Two fluorophores and two spin probes were used to monitor the characteristics of membranes made from a commercial mixture of phosphatidylcholine. Resveratrol was positioned rather in the inner part of the liposome membranes causing reduction in membrane fluidity. Moreover, resveratrol induced a concentration-dependent decrease in the gel-to-liquid crystalline phase transition temperature (from 41.3 ...
Please send the details of your project to [email protected], or call 512-433-6177 and we will be happy to provide an immediate price quote. Experimental details will help us provide an accurate quote and timeline estimate. ...
Liposomes are sphere-shaped vesicular structures self-assembled in a solvent composed of a broad type of lipids or other ... The vesicle structure of liposomes improves the effects on drug penetration through biological membranes, which enhance ... "Liposomes in Cosmetics". Journal of Skin and Stem Cell. Retrieved April 29, 2020. Akbarzadeh, Abolfazl; Rezaei-Sadabady, Rogaie ... "Liposome: classification, preparation, and applications". Nanoscale Research Letters. 8 (1): 102. Bibcode:2013NRL.....8..102A. ...
Dietrich Arndt; Reiner Zeisig; Ines Eue & Iduna Fichtner (1995). "Alkylphosphocholines and Alkylphosphocholine Liposomes". ... Journal of Liposome Research. 5 (1): 91-98. doi:10.3109/08982109509039910. v t e. ... "Cytotoxic effects of alkylphosphocholines or alkylphosphocholine-liposomes and macrophages on tumor cells". Anticancer Research ...
Nanomedicine, the general field Micelle, lipid cored Liposome, lipid bilayer shell, an earlier form with some limitations ... Lasic, Danilo D. (1997). Liposomes in Gene Delivery. Boca Raton: CRC Press. p. 191. ISBN 9780849331091. Retrieved 11 January ... In addition, polymeric nanoparticles, self-emulsifying delivery systems, liposomes, microemulsions, micellar solutions and ...
Immunoliposomes are antibody-conjugated liposomes. Liposomes can carry drugs or therapeutic nucleotides and when conjugated ...
Lipoplexes can also be formed from cationic liposomes and DNA solutions, to yield transfection agents. Cationic liposomes cross ... A mechanism for liposome transport across the BBB is lipid-mediated free diffusion, a type of facilitated diffusion, or lipid- ... Liposomes have the potential to protect the drug from degradation, target sites for action, and reduce toxicity and adverse ... Liposomes can also be functionalized by attaching various ligands on the surface to enhance brain-targeted delivery. Another ...
These drug-loaded liposomes travel through the system until they bind at the target site and rupture, releasing the drug. In ... Note- the term "liposome" is in essence synonymous with "vesicle" except that vesicle is a general term for the structure ... The first stealth liposomes were passively targeted at tumor tissues. Because tumors induce rapid and uncontrolled angiogenesis ... The most significant advance in this area was the grafting of polyethylene glycol (PEG) onto the liposome surface to produce " ...
Doxorubicin HCl liposome (Doxil/Caelyx) - PEGylated liposome containing doxorubicin for the treatment of cancer (Alza, 1995) ... Milla, P; Dosio, F (13 January 2012). "PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the ... ISBN 978-0-444-64082-6. OCLC 1127111107.CS1 maint: others (link) Balazs, Daniel; Godbey, WT (29 October 2010). "Liposomes for ... Irinotecan liposome (Onivyde) - PEGylated liposomal irinotecan hydrochloride trihydrate for the treatment of metastatic ...
Liposome formulations that encapsulate anti-cancer drugs for selective uptake to tumors via the EPR effect include: Doxil and ... These efforts include protein capsids and liposomes. However, as some important, normal tissues, such as the liver and kidneys ... Palmer TN, Caride VJ, Caldecourt MA, Twickler J, Abdullah V (March 1984). "The mechanism of liposome accumulation in infarction ... "Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence ...
In liposomes Osawa (2009) showed FtsZ is capable of exerting a contractile force with no other proteins present. Erickson (2009 ... Osawa M, Anderson DE, Erickson HP (May 2008). "Reconstitution of contractile FtsZ rings in liposomes". Science. 320 (5877): 792 ...
Bicelles are much smaller than liposomes, and so can be used in experiments such as NMR spectroscopy where the larger vesicles ... F Szoka and D Papahadjopoulos."Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)." Annual Review ... "Quantifying the effects of melittin on liposomes". Biochimica Et Biophysica Acta. 1768 (1): 13-20. doi:10.1016/j.bbamem.2006.05 ... is achieved by exposure of the lipid coated gold substrate to outer layer lipids either in an ethanol solution or in liposomes ...
"Preparation and characterization of glycolipid-bearing multilamellar and unilamellar liposomes". Liposome Methods and Protocols ... the role of glycosphingolipids as biological receptors through studies on lectin-glycolipid interactions using liposomes. He ...
Sendai virus-induced agglutination of liposomes containing glycophorin". Biochimica et Biophysica Acta (BBA) - Biomembranes. ... F protein is responsible for this induction because reconstituted liposomes containing F protein can stimulate IL-6 production ... F protein is responsible for this induction because reconstituted liposomes containing F protein can stimulate IL-6 production ... "Membrane penetration of Sendai virus glycoproteins during the early stages of fusion with liposomes as determined by ...
Surolia, Bachhawat B. K.; Podder S. K. (1975). "Interaction between lectin from Ricinus communis and liposome containing ... Mumtaz, Ghosh C.; Bachhawat B. K. (1991). "Design of liposomes for circumventing the reticuloendothelial cells". Glycobiology. ... a hereditary disease of the brain His studies on sugar-bearing liposomes led to its use as a carrier for in situ delivery of ... using sugar-bearing liposomes. He also worked on the therapy of systemic fungal infections by developing liposomal formulations ...
He is best known for his research on liposomes. He was married to Rosalind; they had four children and eleven grandchildren. ... doi:10.1016/S0140-6736(10)60950-6. "Alec Bangham - 'father of liposomes' - dies aged 88". Archived from the original on 29 ... was a British biophysicist who first studied blood clotting mechanisms but became well known for his research on liposomes and ...
In 1993, Martinon demonstrated that liposome-encapsulated RNA could stimulate T-cells in vivo, and in 1994, Zhou & Berglund ... Malone RW, Felgner PL, Verma IM (August 1989). "Cationic liposome-mediated RNA transfection". Proceedings of the National ...
Ellens, H; Bentz, J; Szoka, FC (1985). "H+- and Ca2+-induced fusion and destabilization of liposomes". Biochemistry. 24 (13): ... "A DNA-Programmed Liposome Fusion Cascade". Angewandte Chemie International Edition. 56 (43): 13228-13231. doi:10.1002/anie. ... "Drug Delivery via Cell Membrane Fusion Using Lipopeptide Modified Liposomes". ACS Central Science. 2 (9): 621-630. doi:10.1021/ ... "A simple fluorescent method to determine complement-mediated liposome immune lysis". Journal of Immunological Methods. 15 (3): ...
Tsuji, Gakushi; Fujii, Satoshi; Sunami, Takeshi; Yomo, Tetsuya (2016-01-19). "Sustainable proliferation of liposomes compatible ...
Movassaghian, S; Moghimi, HR; Shirazi, FH; Torchilin, VP (Dec 2011). "Dendrosome-dendriplex inside liposomes: as a gene ...
... working on Liposomes as immunomodulators and drug delivery using Liposomes and he secured a PhD degree for his thesis, ... Immunogenicity of carbohydrate determinants mediated through Liposomes: Liposome-mediated drug delivery from the University of ... Debi P Sarkar; Komal Ramani; Sandeep K Tyagi (2002). "Targeted Gene Delivery by Virosomes". Liposome Methods and Protocols: 163 ...
This liposome-encapsulated form is also approved by the FDA for treatment of ovarian cancer and multiple myeloma. A non- ... Unlike Doxil, the Myocet liposome does not have a polyethylene glycol coating, and therefore does not result in the same rate ... There is a pegylated (polyethylene glycol coated) liposome-encapsulated form of doxorubicin, sold as Doxil. It was developed to ... Versions that are pegylated and in liposomes are also available; however, are more expensive. Doxorubicin was originally made ...
Other nanocapsule shells include liposomes, along with polysaccharides and saccharides. Polysaccharides and saccharides are ...
"Functional reconstitution into liposomes of purified human RhCG ammonia channel". PLOS ONE. 5 (1): e8921. doi:10.1371/journal. ...
Now, scientists plan to take full advantage of the 40 years of progress in liposome development to enhance this transportation ... Shortly after the first description of liposomes, by British haematologist Dr Alec D Bangham in 1961 (published 1964), at the ... Vesosome structure has taken advantage of the progress in liposome development as steric stabilization, pH loading of drugs (it ... They can be considered multivesicular vesicles (MVV) and are, therefore, liposome derived structures. Vesosomes consist of one ...
For example, liposome-based nanoparticles can be biologically degraded after delivery, thus minimizing the risk of accumulation ... Lian, T. and R.J.Y. Ho, Trends and Developments in Liposome Drug Delivery Systems. Journal of Pharmaceutical Sciences, 2001. 90 ... Malam, Y., M. Loizidou, and A.M. Seifalian, Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends ... Malam, Yogeshkumar; Loizidou, Marilena; Seifalian, Alexander M. (November 2009). "Liposomes and nanoparticles: nanosized ...
September 2000). "Long circulating liposomes encapsulating organophosphorus acid anhydrolase in diisopropylfluorophosphate ... organophosphorous intoxication and protect against the effects of diisopropylfluorophosphate when encapsulated in liposomes. ...
Although cationic liposomes have been widely used as an alternative for gene delivery vectors, a dose dependent toxicity of ... Virosomes are one example; they combine liposomes with an inactivated HIV or influenza virus. This has been shown to have more ... Also as a result of their charge, cationic liposomes interact with the cell membrane, endocytosis was widely believed as the ... Examples of cargo molecules of CPPs include nucleic acids, liposomes, and drugs of low molecular weight. CPP cargo can be ...
Heneweer, Carola; Gendy, Samuel EM; Peñate-Medina, Oula (May 2012). "Liposomes and inorganic nanoparticles for drug delivery ...
Liposomes as a carrier for mannophosphoinositide antigens of mycobacteria. Indian J. Biochem. Biophys. 30:160-165. Fratti, R. A ...
The substance is applied encapsulated into liposomes (L-MTP-PE). Being a phospholipid, it accumulates in the lipid bilayer of ... "Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of ... the liposomes in the infusion. One method of synthesis (shown first) is based on N,N'-dicyclohexylcarbodiimide (DCC) assisted ...
The most common vehicle currently used for targeted drug delivery is the liposome. Liposomes are non-toxic, non-hemolytic, and ... Liposomes can be used as drug delivery for the treatment of tuberculosis. The traditional treatment for TB is skin to ... The liposome delivery system allows for better microphage penetration and better builds a concentration at the infection site. ... Thus, by grafting these liposomes with a desired drug to deliver to a region of the body, magnetic positioning could aid with ...
In particular, the present invention provide methods of generating gas-containing liposomes where the gas is introduced under ... liposomes with gas, to generate a gas-liposome dispersion; and thawing said gas-liposome dispersion to generate a plurality of ... liposomes with gas, to generate a gas-liposome dispersion; and thawing said gas-liposome dispersion to generate a plurality of ... wherein the liposomes comprise nitric oxide gas. In certain embodiments, the liposomes the liposomes comprise at least 5 ul, at ...
Liposomes are used in drug delivery, including vaccines. They prevent healthy cells from receiving the drug and prevent the ... A liposome is a vesicle with walls made of phospholipids. ... A liposome is a vesicle with walls made of phospholipids. ... Liposomes were first discovered in England by Alec C. Bangham in 1961. He found that when phospholipids were combined with ... Liposomes are used in drug delivery, including vaccines. They prevent healthy cells from receiving the drug and prevent the ...
The scientific research about liposomes and how they can be applied for use has contributed to a breakthrough method for ... New method for quantification of liposome formulated drugs. *Revolutionary instrument for characterizing liposomes and liposome ... The liposomes are now referred to as stealth liposomes.. Prospective Research. The scientific research regarding the properties ... Additionally, most stealth liposomes are connected to a biological species ligand that has an effect on the expression and drug ...
Liposomes are used as models for artificial cells. Liposomes can also be designed to deliver drugs in other ways. Liposomes ... A liposome is a spherical vesicle having at least one lipid bilayer. The liposome can be used as a drug delivery vehicle for ... Liposomes can also be decorated with opsonins and ligands to activate endocytosis in other cell types. The use of liposomes for ... Another strategy for liposome drug delivery is to target endocytosis events. Liposomes can be made in a particular size range ...
The HORIBA SZ-100 Nanoparticle Size Analyzer can measure the size of liposomes quickly and easily. Additionally, the SZ-100 can ... SZ-100 Liposome Size Results. A small volume of liposome sample was purchased for analysis. The small volume necessitated using ... The amount of drug loaded into the liposomes and the size of the liposomes play pivotal roles in the pharmacokinetic and ... Particle Size Analysis of Liposomes using Dynamic Light Scattering. Liposomes are bilayer vesicles made of phospholipids ...
Cationic liposomes are structures that are made of positively charged lipids and are increasingly being researched for use in ... They are also able to interact with negatively charged cell membranes more readily than classical liposomes. Fusion between ... Upon interacting with negatively charged DNA, cationic liposomes form clusters of aggregated vesicles. At a critical density ... This process bypasses the endosomal-lysosomal route which leads to degradation of anionic liposome formulations. Cationic ...
The great structural versatility of liposomes, their relatively inoccuous nature and ability to incorporate a wide spectrum of ... Y.E. Rahman, Liposomes and chelating agents, in: "Liposomes in Biological Systems", G. Gregoriadis, ed., John Wiley, Chichester ... G. Gregoriadis, Liposomes as carriers for drugs and vaccines, Trends in Biotechnology, 3:235 (1985)CrossRefGoogle Scholar ... B. Wolff and G. Gregoriadis, The use of monoclonal anti-Thy1 IgG1 for the targeting of liposomes to AKR-A cells in vitro and in ...
... Anna Tanka-Salamon,1 Attila Bóta,2 András Wacha,2 Judith ... "Structure and Function of Trypsin-Loaded Fibrinolytic Liposomes," BioMed Research International, vol. 2017, Article ID 5130495 ...
... Anna Tanka-Salamon,1 Attila Bóta,2 András Wacha,2 Judith ... V. Saxena, C. G. Johnson, A. H. Negussie, K. V. Sharma, M. R. Dreher, and B. J. Wood, "Temperature-sensitive liposome-mediated ... conjugated thermosensitive liposomes (HER2 + affisomes)," Journal of Controlled Release, vol. 153, no. 2, pp. 187-194, 2011. ...
In medicine, liposomes containing drugs or other substances are used in the treatment of cancer and other diseases. Drugs given ... in liposomes may have fewer side effects and work better than the same drugs given alone. ... A liposome is a very tiny, fat-like particle that is made in the laboratory. ... Liposome Manufacturing. Read More Liposome Research. Read More Liposome Uses. Read More ...
Selective targeting of ligand-targeted liposomes containing anticancer drugs or therapeutic genes to cell surface receptors ... Ligand-targeted liposomes for cancer treatment Curr Drug Deliv. 2005 Oct;2(4):369-81. doi: 10.2174/156720105774370159. ... Targeting of liposomes to solid tumors, versus angiogenic endothelial cells versus vascular targets is discussed. Ligand- ... Some recent advances in the field of ligand-targeted liposomes for the treatment of cancer are summarized including: selection ...
Trehalose liposomes for the suppression of tumor growth along with apoptosis [in Japanese] 松本 陽子 ... Basic Challenges for Liposome Applications and Their Possible Solutions: Membrane Structure and Confinement [in Japanese] ... Development of drug and cell delivery system for active targeting based on magnetic liposomes [in Japanese] Kono Yusuke ... Handling System of Minute Volume Using the Hydrogel Encapsulating Liposomes [in Japanese] Katsuta S. , Okano T. , Suzuki H. ...
Purchase Advances in Planar Lipid Bilayers and Liposomes, Volume 5 - 1st Edition. Print Book & E-Book. ISBN 9780123736871, ... Advances in Planar Lipid Bilayers and Liposomes, Volume 5 1st Edition. 0.0 star rating Write a review ... Liposomes as a Tool for the Study of the Chronic Actions of Short-lived Peptides in Specific Sites of the Brain (F. Frézard et ... The Novel Liposome Preparation Methods Based on In-water Drying and Phase Separation: Microencapsulation Vesicle Method and ...
Purchase Advances in Planar Lipid Bilayers and Liposomes, Volume 12 - 1st Edition. Print Book & E-Book. ISBN 9780123812667, ... Advances in Planar Lipid Bilayers and Liposomes, Volume 12 1st Edition. 0 star rating Write a review ... 7. Transformation between liposomes and cubic phases of biological lipid membranes induced by modulation of electrostatic ... Advances in Planar Lipid Bilayers and Liposomes, Volume 9, continues to include invited chapters on a broad range of topics, ...
Deml, R.A., Bruckdorfer, K.R. and van Deenen, L.L.M.: The effect of sterol structure on the permeability of liposomes to ... de Gier, J. Mandersloot, J. G. and van Deenen, L.L.M.: Lipid composition and permeability of liposomes.Biochim. Biophys. Acta ... Bittman, R., Leventhal, A.M., Karp, S., Blau, B., Tremblay, P.A., and Kates, M.: Osmotic behavior of liposomes of ... Yoshikawa, W., Akutsu, H. and Kyogoku, Y.: Light-scattering properties of osmotically active liposomes.Biochim. Biophys. Acta ...
Here we report that the attachment of hollow gold nanoshells to the surface of robust liposomes results in a construct that is ... To our knowledge, this is the first example of nanoparticle-liposome system that can be activated by both laser and acoustic ... Here hollow gold nanoshells tethered to liposomes allows the controlled release of encapsulated neurochemicals by acoustic or ... The unique surface plasmon resonance of hollow gold nanoshells can be used to achieve drug release from liposomes upon laser ...
Advice and warnings for the use of Vincristine liposome (Marqibo) during pregnancy. FDA Pregnancy Category D - Positive ... Vincristine liposome Pregnancy and Breastfeeding Warnings. Vincristine liposome is also known as: Marqibo ... Vincristine liposome Breastfeeding Warnings. Most sources consider breastfeeding to be contraindicated during maternal ...
Liposomes - microscopic phospholipid bubbles with a bilayered membrane structure - have received a lot of attention during the ... Recent advances with liposomes as pharmaceutical carriers Nat Rev Drug Discov. 2005 Feb;4(2):145-60. doi: 10.1038/nrd1632. ... Liposomes - microscopic phospholipid bubbles with a bilayered membrane structure - have received a lot of attention during the ...
... liposomes have been studied in depth, and they continue to constitute a field of intense research. Liposomes are valued for ... In this review, we briefly analyze how the efficacy of liposomes depends on the nature of their components and their size, ... Notable progress has been made, and several biomedical applications of liposomes are either in clinical trials, are about to be ... Moreover, we discuss the influence of the physicochemical properties of liposomes on their interaction with cells, half-life, ...
C) 124 nm PEG-liposomes (both feet); (D) 124 nm Negative-liposomes (both feet). ... Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles.. Cai S1, Yang Q, Bagby TR, Forrest ML. ... Thoracic images in posterior view obtained after 99mTc-Liposome aerosol inhalation, in the pig n° 18. a) 5 min after the ... Gamma camera images of the lower portion of rabbits following subcutaneous injection (0.3 ml) of various [99mTc] liposomes in ...
Experimental: Liposomes Intravesical instillation of Liposomes in sterile water totally 40 cc at four weekly treatments. ... Intravesical Liposomes for Ulcerative Cystitis. The safety and scientific validity of this study is the responsibility of the ... At each treatment visit, the patients will have a solution of liposomes instilled in the bladder with a catheter, retained for ... The primary objective is to determine the impact of 4 weekly bladder instillations of liposomes on symptoms in one patient with ...
Taiwan Liposome has been struggling lately, but the selling pressure may be coming to an end soon. ... Taiwan Liposome Company, Ltd. TLC has been struggling lately, but the selling pressure may be coming to an end soon. That is ... Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) : Free Stock Analysis Report. To read this article on click here. ...
The polymerized imaging enhancement liposome particles interact with receptor targets holding the image enhancement agent to ... Polymerized liposome particles based upon lipids having a polymerizable functional group and a metal chelator to attach an ... imaging enhancement agent and lipids having an active targeting group to provide targeted polymerized liposome contrast agents ... 1. A polymerized liposome image contrast agent composition consisting essentially of: liposome forming lipids, said liposome ...
Tell your doctor or nurse right away if you have the following symptoms with this medicine: anxiety; blurred vision; depression; drowsiness; lightheadedness; nausea or vomiting; numbness and tingling of the mouth or lips; restlessness; ringing in the ears; speech problems; or tremors. This medicine may cause serious allergic reactions, including anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Call your doctor right away if you have a rash; itching; fever; increased sweating; lightheadedness or fainting; trouble breathing; trouble swallowing; or any swelling of your hands, face, mouth, or throat after receiving this medicine. ...
Portions of this document last updated: Sept. 01, 2020. Copyright © 2020 IBM Watson Health. All rights reserved. Information is for End Users use only and may not be sold, redistributed or otherwise used for commercial purposes.. ...
A cluster of liposomes. These are spherical lipid bilayers used in drug delivery and gene therapy. They fuse with the cell ... A cluster of liposomes. These are spherical lipid bilayers used in drug delivery and gene therapy. They fuse with the cell ... Credit: Liposomes. Credit: Annie Cavanagh. Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) ...
Liposome. Liposomes are artificially prepared vesicles made of lipid bilayer. Liposomes can be filled with drugs, and used to ... Though liposomes can vary in size from low micrometer range to tens of micrometers, unilamellar liposomes, as pictured here, ... Building a better liposome. Using computational modeling, researchers at Carnegie Mellon University, the Colorado School of ... Liposomes can be composed of naturally derived phospholipids with mixed lipid chains (like egg phosphatidylethanolamine) or ...
Liposomes are frequently utilized to deliver key actives, with hyaluronic acid winning the award for most popular and hydration ... In it, liposomes deliver essential moisture to the skin.. Finally, Osmosis coats its ingredients with a liposome called ... Liposomes are tiny delivery vehicles that transport ingredients into the skin. Made from lipids, liposomes simulate skins ... Some liposomes, e.g., Transfersomes and deformable liposomes, appear to penetrate fully intact into skin. ...
... used to introduce these substances into a cell or specified tissueOrigin of liposome lipo- + -some... ... liposome definition: a synthetic, microscopic globule consisting of layers of lipids encapsulating certain substances (as ... liposome. lip·o·some. a synthetic, microscopic globule consisting of layers of lipids encapsulating certain substances (as ... liposome. noun. A microscopic artificial vesicle consisting of an aqueous core enclosed in phospholipid molecules, used to ...
  • A less desirable form are multivesicular liposomes in which one vesicle contains one or more smaller vesicles. (
  • Liposomes are bilayer vesicles made of phospholipids derived from natural or man-made materials. (
  • Upon interacting with negatively charged DNA, cationic liposomes form clusters of aggregated vesicles. (
  • The ability of liposomes to encapsulate hydrophilic or lipophilic drugs have allowed these vesicles to become useful drug delivery systems. (
  • Natural and synthetic lipids self-assemble in water to form micelles, fibers, sheets, vesicles, and liposomes , which are important materials for analytical chemistry. (
  • Liposomes are artificially prepared vesicles made of lipid bilayer. (
  • Polymerized Liposomes and Vesicles 10. (
  • Liposomes may be generally defined as closed vesicles having a lipid membrane surrounding an entrapped aqueous core. (
  • c) an amount of water, the proportion by weight of (a) to (b) being from 40:1 to 1:20, such that, on addition of excess water, the composition spontaneously forms vesicles or liposomes. (
  • Liposomes are small spherical-shaped artificial vesicles synthesized from phospholipids and cholesterol. (
  • Structurally, liposomes are classified into the following groups: multilamellar large vesicles (MLV), oligolamellar vesicles (OLV), unilamellar vesicles (UV), small unilamellar vesicles (SUV), medium-sized unilamellar vesicles (MUV), large unilamellar vesicles (LUV), giant unilamellar vesicles (GUV), and multivesicular vesicles (MVV). (
  • In terms of preparation method used, liposomes can be classified into the following types: reverse phase evaporation method for single or oligolamellar vescile (REV), multilamellar vesicles (MLV) made by reverse phase evaporation method, stable plurilamellar vesicles, (FATMLV) frozen and thawed, vesicles prepared by extrusion method (VET), vesicles prepared by fusion (FUV), vesicles prepared by french press (FPV), dehydration?rehydration vesicles (DRV), and bubblesomes (BSV). (
  • Liposomes, the microsocopic lipid vesicles that scientists have been making in great variety, are rapidly entering clinical medicine and are expected to improve how many diseases are treated. (
  • Liposomes are vesicles composed of a bilayer (uni-lamellar) and/or a concentric series of multiple bilayers (multi-lamellar) separated by aqueous compartments formed by amphipathic molecules such as phospholipids that enclose a central aqueous compartment. (
  • Liposomes belong to the class of nanosized unilamellar phospholipid bilayer vesicles. (
  • A liposome is a spherical-shaped vesicle that is composed of one or more phospholipid bilayers, which closely resembles the structure of cell membranes. (
  • Liposomes - microscopic phospholipid bubbles with a bilayered membrane structure - have received a lot of attention during the past 30 years as pharmaceutical carriers of great potential. (
  • 17 . The liposome of claim 16 , wherein the phospholipid comprises distearoyl phosphatidylcholine (DSPC) and the sterol comprises cholesterol. (
  • The liposome, from which the LDS is formed, is a phospholipid bilayer formed into an enclosed sack. (
  • To evaluate liposome formulations for use as intracellular sustained-release drug depots, we have compared the uptake and degradation in rat liver and spleen of liposomes of various compositions, containing as their bulk phospholipid an ether-linked phospholipid or one of several ester-linked phospholipids, by perturbed angular correlation spectroscopy. (
  • We found that MLVs but not SUVs, having DHPC as their bulk phospholipid, showed an increased resistance against lysosomal degradation as compared to other phospholipid-containing liposomes. (
  • Microstructure of liposomes was explored by fluorescent probes, and it was found that the BHA was encapsulated in polar groups of phospholipid in the bilayer of liposomes. (
  • The major types of liposomes are the multilamellar vesicle (MLV, with several lamellar phase lipid bilayers), the small unilamellar liposome vesicle (SUV, with one lipid bilayer), the large unilamellar vesicle (LUV), and the cochleate vesicle. (
  • Volume 5 presents recent research on both planar lipid bilayers and liposomes based on their historic and experimental realization. (
  • Advances in Planar Lipid Bilayers and Liposomes, Volume 5, continues to include invited chapters on a broad range of topics, covering both main arrangements of the reconstituted system, namely planar lipid bilayers and spherical liposomes. (
  • This volume keeps in mind the broader goal with both systems, planar lipid bilayers and spherical liposomes, which is the further development of this interdisciplinary field worldwide. (
  • Advances in Planar Lipid Bilayers and Liposomes, Volume 11 includes invited chapters on a broad range of topics, covering both of the main arrangements of the reconstituted system, namely planar lipid bilayers and spherical liposomes. (
  • This volume addresses the broader goal with both systems, planar lipid bilayers and spherical liposomes, which is the further development of this interdisciplinary field worldwide. (
  • The effect of the finite size of one-component liposomes on their phase behavior is investigated via simulations of an implicit- solvent model of self-assembled lipid bilayers. (
  • Liposomes, lipid bilayers and model membranes. (
  • Advances in Planar Lipid Bilayers and Liposomes volumes cover a broad range of topics, including main arrangements of the reconstituted system, namely planar lipid bilayers as well as spherical liposomes. (
  • Although the origin and the basic meaning of the terms "planar lipid bilayers" and "liposome" have not changed during the years, the present advances in the scientific, technological, biomedical and consumer product fields are remarkable. (
  • Ever since its launch the "Ad ances in Planar Lipid Bilayers and Liposomes ' (APLBL) has provided a global platform for a community of researchers having very broad scientific interests in theoretical, experimental and simulation studies on lipid and cell membrane micro and nanostructures. (
  • A liposome can be hence loaded with hydrophobic and/or hydrophilic molecules. (
  • said hydrophilic head groups and said hydrophobic tail groups linked to said liposome forming lipid by a variable length linker portion selected from the group consisting of variable length polyethylene glycol, polypropylene glycol and polyglycine. (
  • 2. A polymerized liposome image contrast agent composition according to claim 1 wherein said active hydrophilic head group is diethylenetriamine pentaacetic acid and said hydrophobic tail group is diacetylene. (
  • A polymerized liposome image contrast agent composition according to claim i wherein said hydrophilic head group comprises a lanthanide-diethylenetriamine pentaacetic acid chelate. (
  • 7. A polymerized liposome image contrast agent composition according to claim 6 wherein said additional hydrophilic head groups are selected from the group consisting of biotin, amine, carboxylic acid and isothiocyanate. (
  • According to Polla, liposomes can carry hydrophilic (water-loving) substances and/or lipophilic (lipid-, oil- or fat-loving) substances. (
  • Due to these properties liposomes have an advantage of encapsulating hydrophobic as well as hydrophilic drugs and delivering them to the targeted site in the body. (
  • In the proposed program, Luna will demonstrate the feasibility of a liposome-based therapeutic delivery system capable of delivering hydrophilic and hydrophobic therapeutics to the traumatically injured brain. (
  • Thus, the liposome is widely used as a delivery system for hydrophilic drugs, although its stability remains to be optimized. (
  • We report on the transport of hydrophilic silica nanoparticles into large unilamellar neutral DOPC liposomes via an internalization process. (
  • Depending on the lipids used, and the orientation of hydrophobic or hydrophilic heads or tails, liposomes can be designed to resist interference from the immune system - or to protect healthy cells from the toxic payload - in order to enhance drug delivery. (
  • To enhance the stability of liposomes in systemic circulation, a number of liposomes modified with hydrophilic polymer such as poly(ethylene oxide) have been developed. (
  • The liposome can be used as a drug delivery vehicle for administration of nutrients and pharmaceutical drugs, such as lipid nanoparticles in mRNA vaccines, and DNA vaccines. (
  • Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. (
  • This manuscript reviews recent advances in the field of lymphatic drug delivery and imaging and focuses specifically on the development of liposomes and solid lipid nanoparticles for lymphatic introduction via the subcutaneous, intestinal, and pulmonary routes. (
  • A new method that turns liposomes into tiny nanoparticle factories supports the step towards using gold nanoparticles in biological probes and drug delivery. (
  • We thought since the liposomes were so small, we expected the nanoparticles to be smaller than when synthesized in a more conventional way, but surprised they were all so similar in size. (
  • We also did not anticipate that the nanoparticles would be so much smaller when prepared inside liposomes compared to regular bulk synthesis. (
  • There are several ways to produce gold nanoparticles and liposomes - tiny bubbles with a thin membrane of lipids - turned out to be reaction vessels well suited to producing gold nanoparticles. (
  • Researchers have attempted to synthesize gold nanoparticles in liposomes before, but the results have been inconsistent, with random-sized nanoparticles or a poor yield. (
  • Traditionally, researchers have made the gold nanoparticles first and then packaged them inside the liposomes for delivery. (
  • They synthesized the gold nanoparticles inside the liposomes, taking away the need to package them after synthesis. (
  • The gold nanoparticles were synthesized inside palmitoyl oleoyl phosphocholine (POPC) liposomes, and had an average size of 2.8 ± 1.6 nm. (
  • We were able to synthesize better quality gold nanoparticles without having to modify existing liposome preparation techniques and without the need for additional stabilizing agents," said Dr. Gudlur. (
  • In order to contribute to a better knowledge of the events involved in the formation of the protein corona when nanoparticles (NPs) come in contact with proteins, we report a study about the changes on the physicochemical properties of pristine, PEGylated and Cyclic Arginine-Glycine-Aspartate peptide (RGD)-functionalized large unilamelar liposomes (LUVs) or magnetoliposomes (MLs) upon incubation with Bovine Serum Albumin (BSA). (
  • Nanoparticles such as liposomes and gold nanoparticles are now considered to be not only efficient drug carriers but also potent adjuvants useful for vaccine formulations. (
  • Nanoparticle-loaded liposomes were separated from unencapsulated nanoparticles by size exclusion chromatography and their characteristics were investigated. (
  • Dual-color, two-photon fluorescence correlation spectroscopy was used to measure the number of nanoparticles inside each liposome. (
  • Results indicated that nanoparticle-loaded liposomes were formed and separated from unencapsulated nanoparticles by using Sepharose gel. (
  • As expected, fluorescence self-quenching of nanoparticles inside liposomes was not observed. (
  • Our work showed that both QDs and SNs were encapsulated into liposomes and it provided a methodology to measure the number of nanoparticles inside each liposome with fluorescence correlation spectroscopy. (
  • Manufacture of liposome nanoparticles is an important step in the delivery of gene therapeutics for treatment of cancer. (
  • We need to check for the stability of these liposomes and the nanoparticles, worry about the circulation time, toxicity, targeting and uptake by cells - a lot of things. (
  • The polymerized imaging enhancement liposome particles interact with receptor targets holding the image enhancement agent to specific sites providing in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology. (
  • Liposomes are composite structures made of phospholipids and may contain small amounts of other molecules. (
  • Liposomes can also gravitate to the skin surface, where encapsulated molecules directly transfer to the skin. (
  • Liposomes are successfully used for encapsulating various drug molecules such as acyclovir, tropicamaide, chloroquine diphosphate, paclitaxel, and cyclosporine. (
  • The project will investigate a range of small molecules for the treatment of cancer and will investigate their formulation into a range of liposome systems. (
  • In order to attain an optimal fluorescent quantum yield, about 200 to 300 dye molecules can be incorporated per liposome. (
  • Liposomes, which are spherical fat molecules found in cell membranes, can be loaded with CRISPR molecules that can then target specific areas of the body when triggered by light. (
  • Lead author Dr Wei Deng says the team used liposomes - spherical nanostructures of fat molecules very similar to cell membrane material - to carry the CRISPR molecules to the target site in the body. (
  • Biologically active molecules ranging from anti-cancer and anti-microbial agents to chelating agents, peptides, hormones, enzymes, pro-teins, vaccines and genetic materials have all come under consideration for delivery by synthet-ic liposomes. (
  • Rates of diffusion of uncharged and charged solute molecules through porin channels were determined by using liposomes reconstituted from egg phosphatidylcholine and purified Escherichia coli porins OmpF (protein 1a), OmpC (protein 1b), and PhoE (protein E). All three porin proteins appeared to produce channels of similar size, although the OmpF channel appeared to be 7 to 9% larger than the OmpC and PhoE channels in an equivalent radius. (
  • Liposomes are microscopic molecules that have been used for years in cosmetic and drug delivery. (
  • The walls of the liposomes contain small molecules called sono-sensitizers, which are sensitive to ultrasound. (
  • The small sono-sensitizer molecules that the team built into the liposomes are the active component of an already-FDA-approved drug that is currently used in photodynamic therapy. (
  • The other important developments such as use of genetic components as therapeutic molecules have further enhanced the scope of Liposomes based therapy. (
  • Taiwan Liposome Company, Ltd. TLC has been struggling lately, but the selling pressure may be coming to an end soon. (
  • The Taiwan Liposome Company specializes in developing liposomes to improve how drugs are delivered. (
  • George Yeh is the President of Taiwan Liposome Company (TLC) and we thank him for fielding our questions. (
  • The report reviews current pipeline of Taiwan Liposome Company, Ltd. (
  • Product profiles for late stage and clinical stage products of Taiwan Liposome Company, Ltd. (
  • Liposomes are most often composed of phospholipids, especially phosphatidylcholine, but may also include other lipids, such as egg phosphatidylethanolamine, so long as they are compatible with lipid bilayer structure. (
  • 7. The hydrogel particles of claim 1, wherein said liposomes are formed from a lipid material selected from the group selected from the group consisting of phosphatidyl ethers, phosphatidyl esters, phosphatidyl ethanolamine, phosphatidylcholine, glycerides, cerebrosides, gangliosides, sphingomyelin, steroids and cholesterol. (
  • Liposomes composed of egg phosphatidylcholine/yeast phosphatidylinositol/1,2-dioleoyl glycerol ester of melphalan, 8:1:1, by mol, and varying percentages of lipophilic SiaLeX conjugate were labelled with BODIPY-phosphatidylcholine. (
  • Two liposome compositions consisting of phosphatidylcholine/phosphatidylglycerol and phosphatidylcholine/cholesterol are examined. (
  • Paclitaxel was administered intravenously in either multilamellar (MLV) liposomes composed of phosphatidylglycerol/phosphatidylcholine (L-pac) or in the Cremophor EL/ethanol vehicle used for the Taxol formulation (Cre-pac). (
  • Cationic liposomes are structures that are made of positively charged lipids and are increasingly being researched for use in gene therapy due to their favorable interactions with negatively charged DNA and cell membranes. (
  • Polymerized liposome particles based upon lipids having a polymerizable functional group and a metal chelator to attach an imaging enhancement agent and lipids having an active targeting group to provide targeted polymerized liposome contrast agents. (
  • Made from lipids, liposomes simulate skin's structure to more easily pass through or manipulate the skin barrier to deliver their contents. (
  • At temperatures higher than T (u) g , the liposomes are spherical and the lipids in both leaflets lack both positional and chain order. (
  • At temperatures lower than T (i) g , lipids in both the inner and outer leaflets exhibit chain order as well as positional order, and the liposomes become faceted. (
  • The preparation of the liposomes is affected by supersonic starting from a lipid mixture consisting of the matrix lipids soy lecithin, cholesterol, -tocopherol and the perylene dyes. (
  • We have recently established that liposomes composed of cationic lipids act as adjuvant for nasal vaccine formulation. (
  • Once the drug-filled liposomes are injected, ultrasound can be applied to penetrate tissue and cause the sensitizers to create reactive oxygen species , which react with lipids in the walls of the liposomes," Kohane says. (
  • A liposome is a spherical vesicle having at least one lipid bilayer. (
  • In this range of temperatures, liposomes are essentially spherical. (
  • Liposomes are artificially created, microscopic, spherical structures that take a page from na-ture to exploit certain useful properties found in living cells. (
  • Gamma camera images of the lower portion of rabbits following subcutaneous injection (0.3 ml) of various [99mTc] liposomes in each hind foot at either 30 minutes, 60 minutes or 24 hours post injection. (
  • However, liposomes that are administered through intravenous injection are rapidly uptaken by reticuloendothelial system (RES) cells in the liver and spleen. (
  • Aetna considers continuation of vincristine sulfate liposome injection (Marqibo) medically necessary for members with ALL meeting initial selection criteria, and when there is no evidence of unacceptable toxicity or disease progression while on the current regimen. (
  • Vincristine sulfate liposome injection is available as the Marqibo Kit. (
  • Note: Marqibo (vincristine sulfate liposome injection) has different dosage recommendations than vincristine sulfate injection. (
  • The recommended dose of Marqibo (vincristine sulfate liposome injection) is 2.25 mg/m 2 intravenously over 1 hour once every 7 days. (
  • Marqibo (vincristine sulfate liposome injection) is sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate for intravenous administration. (
  • Vincristine sulfate liposome injection (VSLI), sphingomyelin and cholesterol nanoparticle vincristine (VCR), facilitates VCR dose-intensification and densification plus enhances target tissue delivery. (
  • In 2012, Marqibo (vincristine sulfate liposome injection) was approved by the U.S. Food and Drug Administration for the treatment adult patients with Philadelphia chromosome‐negative (Ph‐) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti‐leukemia therapies. (
  • Marqibo (vincristine sulfate liposome injection) is contraindicated in patients with demyelating conditions, including Charcot-Marie-Tooth syndrome. (
  • As opposed to the conventional (non-surface modification) liposomes, we briefly address the issue of the accelerated clearance of PEGylated-liposomes (sterically stabilized liposomes, long-circulating liposomes) on repeated injection, a process that has recently been observed. (
  • After injection of EXPAREL into soft tissue, bupivacaine is released from the multivesicular liposomes over a period of time. (
  • DepoDur ( morphine sulfate) extended-release liposome injection is a long-acting narcotic pain reliever ( opiate -type) used to treat pain after major surgery. (
  • Our DepoDur (morphine sulfate) extended-release liposome injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. (
  • In controlled and open label clinical studies with DepoDur (morphine sulfate xr liposome injection) , the majority of the adverse events were typical of opiate medications and would be expected in the surgical populations studied. (
  • (EN) Disclosed are positively-charged, cytotoxic nanoparticle compositions comprising immune modulators (such as the toll-like receptor (TLR)-4 ligand, monophosphoryl lipid (MPL)-A), and Interleukin (IL)-12)), which exhibit enhanced uptake by mammalian cancer cells, and cause increased cancer cell death and/or an increased release of cancer antigens following direct injection to populations of cancer or tumor cells. (
  • Recovery of 111In-labeled liposomes in blood, liver, and spleen was assessed at specific time points after injection and the percentage of liposomes still intact in liver and spleen was determined by measurement of the time-integrated angular perturbation factor [G22(infinity)] of the 111In label. (
  • Right now, the pain treatment system developed by Kohane's team can be activated by ultrasound up to three days after injection of liposomes, making it well-positioned for future translation as a post-operative pain management strategy. (
  • A new Phase 1 vaccine study began today that will evaluate experimental prime/boost HIV-1 vaccine regimens formulated with combinations of different adjuvants, including one from the Army Liposome Formulation (ALF) family of adjuvants developed by scientists with the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research. (
  • The formulation of lyophilized liposome cakes, micronization of the cake, aerosolization using a dry powder inhaler, and the in vitro distribution of such powders upon aerosolization in a silicone elastomer throat attached to an Andersen cascade impactor are reported. (
  • Liposome formulation prolongs the duration of action. (
  • Liposome drug delivery systems have been instrumental in the formulation of potent drugs to enhance therapeutics. (
  • Therefore, in this review, we focus on the role of serum proteins, so-called opsonins, that enhance the clearance of liposomes, when bound to liposomes. (
  • For spleen, a tissue of the reticuloendothelial system that is important in the clearance of liposomes, the AUC was statistically higher for L-pac. (
  • Among these mechanisms are included the impeding of the fast clearance of liposomes. (
  • Morphology and size of liposomes were obtained by transmission electron microscope and dynamic light scattering technology. (
  • A liposome is a vesicle with walls made of phospholipids. (
  • Though liposomes can vary in size from low micrometer range to tens of micrometers, unilamellar liposomes, as pictured here, are typically in the lower size range with various targeting ligands attached to their surface allowing for their surface-attachment and accumulation in pathological areas for treatment of disease. (
  • 5. The hydrogel particles of claim 1, wherein said liposomes are unilamellar liposomes. (
  • From a multitude of perylene derivatives investigated only those are optimally incorporated inot the bilayer membrane of unilamellar liposomes which are substituted at both nitrogen atoms by one or two linear hydrocarbon groups. (
  • November 12, 2018 -- The ADA has created a new Code on Dental Procedures and Nomenclature (CDT) for Exparel, a bupivacaine liposome injectable suspension from Pacira Pharmaceuticals . (
  • By preparing liposomes in a solution of DNA or drugs (which would normally be unable to diffuse through the membrane) they can be (indiscriminately) delivered past the lipid bilayer, but are then typically distributed non-homogeneously. (
  • As the pH naturally neutralizes within the liposome (protons can pass through some membranes), the drug will also be neutralized, allowing it to freely pass through a membrane. (
  • This is thought to be due to the formation of a 3D network structure caused by the hydrophobic group of HM-HPMC penetrating into the liposomal bilayer membrane, crosslinking the liposomes together. (
  • We synthesized functional polymers to induce membrane fusion in response to weakly acidic pH and modified these polymers onto antigen-loaded liposomes to develop antigen delivery systems for induction of cellular immunity efficiently. (
  • pH-sensitive polymer-modified liposomes were taken up by dendritic cells efficiently and achieved cytoplasmic delivery of antigenic proteins via membrane fusion with endosomal membrane responding to weakly acidic pH in endosomes. (
  • These saponins showed different activites on liposomal membrane, and cholesterol in liposomes was an important factor to this variation of saponin activities. (
  • A phosphorylated fusion peptide can mediate membrane fusion when the phosphates (green triangles, see scheme) are removed by phosphatases (blue spheres), delivering the contents of the liposome into the cytosol. (
  • Furthermore, the liposome size and distribution was found to decline with decreasing membrane pore size. (
  • While the location of the freezing temperature of liposomes with diameters larger than 30 nm is the same as that of a planar membrane, the transition is broadened as the liposome diameters are decreased. (
  • The liposomes allow for a more controllable and easily manipulated system compared to the thylakoid membrane. (
  • As the water-insoluble perylene dyes are incorporated into the bilayer membrane, the aqueous inner volume of the liposomes remains available for a fruther utilization. (
  • Endocytosis of SiaLeX liposomes occurred mostly via clathrin-independent pathways, which does not contradict the available literature data on E-selectin localisation in the plasma membrane. (
  • Part I. Physical PropertiesPreparation, Isolation, and Characterization of Liposomes Containing Natural and Synthetic LipidsSubroto Chatterjee and Dipak K. BanerjeePreparation and Use of Liposomes for the Study of Sphingolipid Segregation in Membrane Model SystemsMassimo Masserini, Paola Palestini, Marina Pitto, Vanna Chigorno, and Sandro SonninoPart II. (
  • The strong adhesive interactions of lipid membrane onto the silica nanoparticle triggered liposome deformation until the formation of a curved neck. (
  • In particular, the method relates to radionuclide labeling of preformed liposomes with or without encapsulated protein by means of a radionuclide carrier characterized as being membrane diffusible. (
  • Continued improvements of bio-membrane sensors and liposome delivery systems that are competent in the association of other membrane-bound proteins in vivo could allow selective delivery of therapeutic compounds to chosen intracellular target areas. (
  • Retrieved on July 19, 2019 from (
  • In Chapter Four, the authors review the mechanisms of drug transport through the BBB using liposomes, and the design strategies for optimum liposomal properties. (
  • To develop liposomal drug delivery system, functional liposomes including antibody-conjugating liposomes known as immunoliposomes and stimuli-triggered liposomes such as pH- and thermo-sensitive liposomes have been investigated in Chapter Seven. (
  • Chapter Ten presents the recent advances of liposomes in drug and vaccine delivery and shed light to the application of DSC to thermodynamic characterization of liposomal delivery platforms. (
  • 5.1.1 Fig. 1 demonstrates that liposomes may become distorted and are difficult to measure and analyze when they are air-dried, while the same liposomal preparation is clearly easier to analyze when the specimen is near-instantly preserved by vitrification. (
  • A liposomal model system based on liposomes formed by oleic acid was used to develop and study the incorporation of PEDOT-S to fatty acid membranes. (
  • The clearance rate of liposomal drugs from the circulation is determined by the rate and extent of both drug release and uptake of liposomes by cells of the mononuclear phagocyte system (MPS). (
  • Efficacy and toxicity profiles of liposomes are based on their characteristic pharmacokinetics, drug release, and disposition after administration. (
  • The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models. (
  • Advantages such as improvement and control over pharmacokinetics and pharmacodynamics, decreased toxicity, and enhanced activity of drugs against intracellular pathogens are key divers for pharmaceutical companies to invest in the global liposomes drug delivery market. (
  • Liposomes have helped to magnify the efficacy - while reducing the toxicity - of chemotherapeutic drugs, for exam-ple. (
  • A majority of liposome formulations are designed to bring down toxicity. (
  • 9 Next, these combinations were incorporated into cationic elastic liposomes (ELs) and in test models, liposomes with HA showed 23% higher wound recovery. (
  • To this end, we have studied the enhancement of antigen uptake by murine dendritic cell line, DC2.4 cells, by the cationic liposomes and the specific pathways involved in the process. (
  • We have observed that the uptake of ovalbumin (OVA) into DC2.4 cells is greatly increased when co-cultured with the cationic liposomes composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl] (DC-chol). (
  • Our results implied, at least in part, that enhanced uptake of antigens induced by the cationic liposomes could be a possible mechanism for the induction of immune responses. (
  • We recently demonstrated that the cationic liposomes composed of 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP) and 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl] (DC-chol), termed as DOTAP/DC-chol liposomes, are served as a potent adjuvant. (
  • The detailed molecular mechanism(s) behind the adjuvant effects of the cationic liposomes are not completely elucidated. (
  • The disclosed cationic liposomes represent an important advance in the area of cancer immunotherapeutics. (
  • Selective targeting of ligand-targeted liposomes containing anticancer drugs or therapeutic genes to cell surface receptors expressed on cancer cells is a recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics or gene therapeutics. (
  • Some recent advances in the field of ligand-targeted liposomes for the treatment of cancer are summarized including: selection criteria for the receptors to be targeted, choice of targeting ligands and choice of encapsulated therapeutics. (
  • Currently, there are limited methods available for longitudinal and non-invasive in vivo assessment of the transport kinetics of carrier-based therapeutics, such as those relying on liposomes. (
  • Presently pharmaceutical products of liposome-based therapeutics exhibit a better understanding of lipid-drug interactions as well as liposome disposition mechanisms. (
  • 2018. Liposome Research . (
  • The U.S. Food and Drug Administration, FDA, published its final guidance for industry on liposome drug products in April 2018. (
  • Importantly, BS-Lips increased the oral bioavailability of PTX by 2.5 and 4-fold, respectively, compared with conventional liposomes (Lips) and Taxol (free drug), thereby displaying a better inhibition of tumor growth that was similar to the group injected intravenously with Taxol. (
  • Intravenously injected liposomes initially come into contact with serum proteins. (
  • The modified liposomes were intravenously injected into the rats, and Kupffer cells were isolated and analyzed by flow cytometry for in vivo gene delivery and expression. (
  • A) Flow cytometry showed that PTP with 2 mol% FP-2PT-Chems liposomes had greater time-dependent uptake than peptide-free liposomes or liposomes with 2 mol% FP-2Sul-Chems. (
  • Therefore, techniques based on surface modification have been developed for preventing the uptake by RES cells in order to increase the liposomes effectiveness. (
  • The increase in SiaLeX content in liposomes led to a proportional increase in their uptake by cytokine-activated cells as opposed to non-activated HUVEC: for 10% SiaLeX liposomes, binding avidity and overall accumulation increased 14- and 6-fold, respectively. (
  • The use of diacyl phospholipids with a high gel/liquid-crystalline phase-transition temperature, such as DPPC and DSPC, also retarded degradation of MLV, but not of SUV in the dose range tested, while the rate of uptake of these liposomes by the liver was lower. (
  • The pharmaceutical industry segment led the global liposomes market due to rapid advancements in targeted drug delivery systems. (
  • Liposomes Market research report gives an insight into global Liposomes market. (
  • Synopsis of the report summarizes the global Liposomes market. (
  • The global liposomes market is analyzed in US$, from 2010 through 2022. (
  • This process bypasses the endosomal-lysosomal route which leads to degradation of anionic liposome formulations. (
  • Continuous manufacturing of liposome formulations incorporating anti-cancer agents: Exploiting novel methods in microfluidics. (
  • The research is focused on developing new formulations and new processes for the production of liposomes for the delivery of anti-cancer agents. (
  • liposome drug products are complex and sensitive formulations and response to CMC changes is less predictable than with more conventional formulations. (
  • The granted claims were directed to pro-liposome compositions, to aerosol compositions and to a method of making an aqueous dispersion of liposomes. (
  • The Novel Liposome Preparation Methods Based on In-water Drying and Phase Separation: Microencapsulation Vesicle Method and Coacervation Method (Tomoko Nii, Fumiyoshi Ishii). (
  • Volume I deals directly with methods for the preparation of liposomes and auxiliary techniques. (
  • Preparation of Solvent Vaporization Liposomes 4. (
  • French Pressure Cell Liposomes: Preparation, Properties, and Potential 5. (
  • The Preparation of Variably Sized Homogenous Liposomes for Laboratory, Clinical and Industrial Use by Controlled Detergent Dialysis 8. (
  • The Preparation of Sterile Drug-Containing Liposomes 11. (
  • In Chapter Five, the development rationales and structural types of pH-sensitive liposomes is discussed Chapter Six presents the characteristic, classification and preparation methods of liposomes. (
  • Larger liposomes (structure and sizes) are preferentially lost during sample preparation. (
  • 1. In accordance with the principles in G 5/83 and subsequent case law, the concept of second or further medical use can only be applied to claims to the use of substances or compositions (here, liposome compositions) for the preparation of a medicament intended for use in a method referred to in Article 52(4) EPC. (
  • The classification of liposomes is based on its structural properties or on the method of preparation used. (
  • When a 0.8 mM solution of 50 nm QDs was used for liposome preparation, each liposome encapsulated an average of three QDs. (
  • The invention relates to the efficient preparation of radionuclide labeled liposomes and radionuclide-labeled liposome-encapsulated protein. (
  • A kit method useful for the convenient preparation of 99m Tc-labeled liposomes or liposome-encapsulated hemoglobin for clinical use is also disclosed. (
  • Specifically, this study evaluated the in vivo pharmacokinetics, in both mice and rabbits, of a liposome-based CT and MR contrast agent previously developed by our research group. (
  • Since laser-stimulated release from HGN-liposome systems has been attributed to a mechanism similar to that underlying ultrasound release 7 , we hypothesised that the system developed for laser use could be further developed to release using ultrasound at therapeutic frequencies. (
  • 3 . The process of manufacture of non-pegylated liposomes of claim 1 further comprising loading the liposomes with a therapeutic or diagnostic agent. (
  • 18 . The liposome of claim 16 , wherein the non-pegylated liposome further comprises a therapeutic or diagnostic agent. (
  • 19 . The liposome of claim 18 , wherein said therapeutic agent comprises an antineoplastic agent. (
  • The aim of this study was to develop bile-salt liposomes (BS-Lips) to enhance the absorption of PTX and thus improve its therapeutic outcome. (
  • In terms of application, the global liposomes drug delivery market can be segmented into therapeutic and clinical. (
  • Hence accurate and rapid measurement of the size of liposomes is essential for novel and effective drug delivery systems. (
  • The HORIBA SZ-100 Nanoparticle Size Analyzer can measure the size of liposomes quickly and easily. (
  • North America is a leading market for liposomes drug delivery systems due to increase in novel technologies in targeted drug delivery systems. (
  • The market for liposomes presents attractive growth opportunities, driven by growing demand for increasingly effective drugs in the field of pharmaceuticals, and niche applications in other emerging areas. (
  • With these readily reproducible methods, investigators can illuminate such critical questions as the attachment of liposmes to cell surfaces, the permeation of liposomes through the plasma membranes, and the stability of liposomes in cellular and nuclear matrices. (
  • Thus, the comb-type copolymer composed of ODA-HPOEM-HEMA can be a promising surface modifier for enhancement of the stability of liposomes in systemic circulation. (
  • The unique surface plasmon resonance of hollow gold nanoshells can be used to achieve drug release from liposomes upon laser stimulation, and adapted to mimic the intricate dynamics of neurotransmission ex vivo in brain preparations. (
  • By enrobing such low-bioavailability substances in liposomes, it's possible to bypass some of the pitfalls of passing through the digestive tract, and to enhance delivery to the bloodstream. (
  • Chapter Three provides an overview of the development and application of liposomes in biomedical sciences, with special emphasis on recent advances in the investigation of multifunctional liposomes that target cells and cellular organelles with a single delivery system. (
  • The application of Liposomes have enormously undergone transformations owing to use in the treatment of solid tumors. (
  • G. Gregoriadis (Ed.) "Liposomes as Drug Carriers: Recent Trends and Progress", John Wiley and Sons, Chichester (1988). (
  • Liposomes as injectable drug carriers have been extensively investigated due to their biocompatibility and effective drug encapsulating property. (
  • Liposomes are employed as drug carriers for targeted drug therapy for various diseases, as they are biocompatible and biodegradable. (
  • Liposomes are of considerable interest because of their value as carriers for diagnostic agents, particularly radiopharmaceuticals for tracer and imaging studies. (
  • To our knowledge, this is the first example of nanoparticle-liposome system that can be activated by both laser and acoustic stimulation. (
  • One promising nanoparticle system which allows for precise temporal control is the addition of near-infrared (NIR) absorbing hollow gold nanoshells (HGNs) to the surface of liposomes 7 . (
  • Cryo-electron tomography of nanoparticle transmigration into liposome. (
  • Basic cell-cell and cell-surface interactions in Liposome and Cellular Systems (U. Gisma et al . (
  • Interactions of antitumour Sialyl Lewis X liposomes with vascular endothelial cells. (
  • Here, we study the impact of SiaLeX ligand on the interactions of liposomes with human umbilical vein endothelial cells (HUVEC) using flow cytometry, spectrofluorimetry and confocal microscopy. (
  • The high fluorescent potential and the exceptional photostability of lipophilic derivatives of perylene-3,4:9,10-bis(dicarboximides) are utilized for the fluorescence-labelling of liposomes. (
  • The size/charge distribution and domain configuration of these liposomes are characterized in detail by confocal fluorescence microscopy, nanosphere binding and zeta potential measurements. (
  • Cytarabine liposome is a long-acting (sustained-release) chemotherapy drug used to treat cancer in the area around the spinal cord (lymphomatous meningitis ). (
  • Marqibo (vinCRIStine liposome). (
  • Along with its needed effects, vincristine liposome may cause some unwanted effects. (
  • Some side effects of vincristine liposome may occur that usually do not need medical attention. (
  • Some side effects of vincristine liposome may not be reported. (
  • Hyperthermia-triggered intracellular delivery of anticancer agent to HER2+ cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER 2 + affisomes)," Journal of Controlled Release , vol. 153, no. 2, pp. 187-194, 2011. (
  • Chapter Eight covers the use of thermosensitive liposomes for drug delivery and cancer therapy, because the side-effects of anticancer drugs are restrained and drug release can be controlled in combination with local hyperthermia. (
  • Dmitri Simberg, PhD, an associate professor in the Department of Pharmaceutical Sciences in the Skaggs School of Pharmacy and a CU Cancer Center member, has released the results of a new study of the effectiveness of different types of fluorescent labels used to monitor the accumulation of liposomes in tumors. (
  • In terms of type of industry, the liposome drug delivery market can be segmented into pharmaceutical, cosmetic, food, and farming. (
  • Pharmaceutical Research"Volume 199 of the series Methods in Molecular BiologyT, offers an excellent overview of protocols used for the study of liposomes in biology. (
  • A liposome design may employ surface ligands for attaching to unhealthy tissue. (
  • Liposomes can also be decorated with opsonins and ligands to activate endocytosis in other cell types. (
  • Liposomes can be modified with different ligands to control their biological properties, such as longevity, targeting ability, and intracellular penetration, in a desired fashion. (
  • Claims 24 to 41 of the same set of claims were directed to aerosol compositions or pro-liposome compositions. (
  • It was argued that all the requests included claims for compositions and processes in which the presence of the water was an optional feature, despite the fact that there was no disclosure in the application as filed of processes carried out by using anhydrous pro-liposome compositions. (
  • In fact, in the view of the opposition division, the expressions 'up to 20% of water' or 'up to 40% of water', which were used in several passages of the application as filed and which, as the appellant contended, implicitly covered anhydrous pro-liposome compositions, did not disclose the figure 0% of water. (
  • They are also able to interact with negatively charged cell membranes more readily than classical liposomes. (
  • The lipid bilayer that defines artificial liposomes mimics the similar lipid bilayer architecture that comprises living cell membranes. (
  • Research from Seoul explored how liposomes containing epidermal growth factors (EGFs) and hyaluronic acid (HA) could aid in the treatment of wounds. (
  • With each drop, the power of the world's first multi-layered Liposome Technology™ and hyaluronic acid instantly soothes, softens, smooths and restores a fresh, youthful radiance for all skin types. (
  • Weissmann - during a Cambridge pub discussion with Bangham - first named the structures "liposomes" after the lysosome, which his laboratory had been studying: a simple organelle the structure-linked latency of which could be disrupted by detergents and streptolysins. (
  • Chapter One is addressed to a comprehensive revision of the bibliography regarding the emergence of liposomes and the first steps in their design, the type of systems (components and structures), their classification and properties. (
  • Larger liposomes, defined to include larger structures and sizes with respect to this practice, are more difficult to image for two reasons. (
  • Liposomes can be prepared by disrupting biological membranes (such as by sonication). (
  • To compare the efficiency of different nanosizing techniques, the following techniques were used to nanosize the liposomes: extrusion, ultrasonication, freeze-thaw sonication (FTS), sonication and homogenization. (
  • EXPAREL is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension of multivesicular liposomes (DepoFoam ® drug delivery system) containing bupivacaine. (
  • Targeting of liposomes to solid tumors, versus angiogenic endothelial cells versus vascular targets is discussed. (
  • The tumors are targeted with Liposomes containing bisphosphonate which reduces the tumor associated macrophages. (
  • The in vitro adsorption and retention of liposomes onto four common types of dental restorative materials (conventional and silorane-based resin composites as well as conventional and resin-modified glass ionomer cements (GIC)) have been investigated due to their potential use in the oral cavity. (
  • In medicine, liposomes containing drugs or other substances are used in the treatment of cancer and other diseases. (
  • In this review, we describe the outline of antibody-modified liposome for active targeting DDS and introduce our recent research on tumor targeting using the antibody-modified liposomes for cancer chemotherapy. (
  • Liposomes can be filled with drugs, and used to deliver drugs for cancer and other diseases. (
  • Encapsulating irinotecan in a liposome helps the drug stay in the circulation longer, so it is more likely to reach and kill cancer cells. (
  • On October 22, the U.S. Food and Drug Administration (FDA) approved irinotecan liposome (Onivyde®) to be used in combination with fluorouracil and leucovorin to treat patients with metastatic pancreatic cancer whose disease has progressed after gemcitabine -based chemotherapy. (
  • FDA Approves Irinotecan Liposome to Treat Pancreatic Cancer was originally published by the National Cancer Institute. (
  • The applications of the Liposome-formulated drugs have multiplied over the years and they are now part of cancer treatment and systemic or local fungal infections. (
  • Particle size results for the liposome. (
  • Conditions are shown which generate liposome encapsulated ODN by electrospray with a particle size of 109 nm. (
  • 11. A composition comprising a plurality of gas-containing liposomes, wherein said gas-containing liposomes comprise at least 15 ul of gas per 5 mg of said gas-containing liposomes. (
  • 8. An immunoreactive, stable liposome in accordance with claim 7 and further comprising a plurality of like liposomes being combined in the presence of a substrate for said enzyme with said liposomes being uniformly dispersed in said substrate. (
  • Using real-time imaging with a high-pressure microscope, we examined the effects of hydrostatic pressure on the morphology of tubulin-encapsulating giant liposomes. (
  • It is advantageous to be able to control the size and morphology of such liposomes. (
  • Liposomes can also be designed to deliver drugs in other ways. (
  • Liposomes that contain low (or high) pH can be constructed such that dissolved aqueous drugs will be charged in solution (i.e., the pH is outside the drug's pI range). (
  • A similar approach can be exploited in the biodetoxification of drugs by injecting empty liposomes with a transmembrane pH gradient. (
  • P.A.H.M. Toonen and D.J.A. Crommelin, Immunoglobulins as targeting agents for liposome-encapsulated drugs, Pharmaceutisch Weekblad Scient. (
  • Drugs given in liposomes may have fewer side effects and work better than the same drugs given alone. (
  • Finally, we describe some strategies developed to overcome limitations of the "first-generation" liposomes, and liposome-based drugs on the market and in clinical trials. (
  • Patients in the trial were randomly assigned to receive treatment with irinotecan liposome alone, irinotecan liposome in combination with the chemotherapy drugs fluorouracil and leucovorin, or with fluorouracil and leucovorin alone. (
  • Certain drugs may be incorporated into liposomes in order to administer them. (
  • A multi-institutional team involving biomedical engineers and scientists from UNSW Sydney found that liposomes - commonly used in pharmacology to encapsulate drugs or genes - can be triggered by light to release the payload in a specific site of the body. (
  • The unique features of Liposome-formulated drugs are that they remain biologically inert, biocompatible and restrict the cause of unwanted toxic or antigenic reactions. (
  • Liposomes are used in drug delivery, including vaccines. (
  • and thawing said gas-liposome dispersion to generate a plurality of gas-containing liposomes. (
  • 2. The method of claim 1, wherein pressure is released from said gas-liposome dispersion prior to said thawing. (
  • 3. The method of claim 1, wherein pressure is released from said gas-liposome dispersion during said thawing. (
  • Liposomes should not be confused with lysosomes, or with micelles and reverse micelles composed of monolayers. (
  • Liposomes can be easily distinguished from micelles and hexagonal lipid phases by negative staining transmission electron microscopy. (
  • The scientific research about liposomes and how they can be applied for use has contributed to a breakthrough method for targeted drug delivery systems. (
  • PEG is known to increase circulatory lifespan, but it also hinders the ability of the liposome to bind to the target delivery site. (
  • Additionally, most stealth liposomes are connected to a biological species ligand that has an effect on the expression and drug delivery. (
  • Several questions about the optimal use of liposome in drug delivery remain, but as research continues there are likely to be more solutions to problems in the future. (
  • Another strategy for liposome drug delivery is to target endocytosis events. (
  • M. Mezei and V. Gulasekharam, Liposomes: A selective drug delivery system for the topical route of administration, Life Sci. (
  • Liposomes are tiny delivery vehicles that transport ingredients into the skin. (
  • Phosphatase-triggered fusogenic liposomes for cytoplasmic delivery of cell-impermeable compounds. (
  • A key focus of our research is the development of liposome based drug delivery systems (LDS). (
  • Liposome Drug Delivery Market : Shares and Strategies For Key. (
  • Thus, liposomes are promising systems for targeted drug delivery. (
  • Development in scientific research in recent years has led to the rapid expansion of the global liposome drug delivery market. (
  • Increased understanding of targeted drug delivery system has fuelled the liposome drug delivery system market. (
  • However, low solubility, short half-life and high production cost are key restraints of the global liposome drug delivery market. (
  • Ongoing research and advancement in liposome design are leading to new applications for the delivery of new biotechnology products such as recombinant proteins antisense oligonucleotides and cloned genes. (
  • Get accurate market forecast and analysis on the Liposome Drug Delivery Market. (
  • The aim of this study was to modify liposomes with a novel mannosylated polyethylene glycol-phosphatidylethanolamine (M-PEG-PE) ligand to achieve active targeted gene delivery. (
  • M-PEG-PE could function as an excellent active targeting ligand, and M-PEG-PE-modified liposomes could be promising active targeted drug delivery vectors. (
  • In Phase I, Luna will demonstrate the feasibility of this delivery system using in vitro models, and in Phase II will demonstrate the functionality of these functionalized liposomes in in vivo TBI models. (
  • Liposomes and related lipid-based technologies are particularly useful in two areas of drug delivery: making more targeted therapies or providing more sustained release of a drug over time. (
  • One advantage is that they are already confined within liposomes, which can be used as biological probes and in drug delivery. (
  • This interdisciplinary project is designed to consider the development of appropriate systems to manufacture liposome-based drug delivery and will be based within two of our research groups: (Prof Perrie and Dr Rattray). (
  • Recently, we showed that tetrasaccharide selectin ligand SiaLeX provided targeted delivery of liposomes loaded in the bilayer with melphalan lipophilic prodrug to tumour endothelium followed by severe injury of tumour vessels in a Lewis lung carcinoma model. (
  • Liposomes are already well established as an extremely effective drug-delivery system," she says. (
  • Dr Deng says because liposomes are the most common and well-established drug delivery vehicles, they are much safer than using viruses. (
  • Unlike the traditional liposome-based delivery systems, our liposomes can be 'turned on' under light illumination," Dr Deng says. (
  • As noted, this patent application describes a liposome for the delivery of an ECM , a method for promoting cell growth, and a method for preparing said liposome. (
  • The use of liposomes is primarily directed at targeted drug delivery. (
  • Out of all the particle delivery systems, I think liposomes are one of the most clinically-acceptable and customizable options out there," Rwei says. (